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ABSTRACT OF DISSERTATION 
SYMPTOM ASSESSMENT AND MANAGEMENT IN PATIENTS WITH HEART 
FAILURE 
Patients with heart failure (HF) must monitor and recognize escalating symptoms 
to manage worsening HF in a timely manner. However, routine symptom monitoring is 
not commonly performed by this population.  
Providing a symptom diary along with an education and counseling session may 
help HF patients promote symptom monitoring and interpretation. The accumulated 
information about changes in daily symptoms will allow patients to easily compare 
current symptom status to the past without depending on memory and can rapidly capture 
worsening HF. To date, few studies have tested the effect of a daily symptom diary. 
The purpose of this dissertation was to develop and test a symptom diary 
intervention to improve outcomes in HF patients. Prior to testing the intervention, 
preliminary work included: (1) determining the impact of symptom clusters on cardiac 
event-free survival; (2) evaluating the quality of existing symptom measures designed for 
HF patients; (3) evaluating the effect of physical symptom items that were often included 
in a depressive symptom instrument on cardiac event-free survival; and (4) evaluating the 
association between symptom monitoring and self-care management. Based on this 
information, a randomized, controlled pilot study was conducted to test the effect of a 
symptom diary with an education and counseling intervention on prognosis, health-
related quality of life (HRQOL), and self-care maintenance at 3 months follow-up. 
A total of 44 hospitalized patients with HF were randomly assigned to either usual 
care or intervention providing a daily symptom diary with education and counseling. 
There were trends toward fewer HF events and improved self-care maintenance in the 
intervention group compared to the usual care group. However, there was no difference 
in HRQOL between the two groups.  
The results of this dissertation suggest the importance of assessing symptom 
clusters and further studies to improve the quality of existing HF symptom measures. 
Results from this dissertation also provided the evidence of the advantages of regular 
symptom monitoring to facilitate early identification of worsening HF and initiation of 
 
timely responses. However, further studies are needed to provide additional evidence of 
the positive impact of a use of daily symptom diary in patients with HF.  
KEYWORDS: heart failure, symptoms and signs, symptom assessment, self-care, 
outcomes. 
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CHAPTER ONE 
Introduction 
Heart failure (HF) is a progressive and complex clinical syndrome manifested by 
multiple symptoms and signs. The prevalence of HF is increasing as longevity increases 
in the population and there is greater survival from acute coronary events.1 In the United 
States, HF affects approximately 5.7 million adults and an additional 3 million adults will 
have HF by 2030.2  
Despite advances in HF management, patients with HF experience a poor 
prognosis and compromised quality of life. Among Medicare beneficiaries from two 
large HF registries, three-month and one-year rehospitalization rates were 40% and 65%, 
respectively. In the same study, the one-year post-discharge mortality rate was 34%.3 
People with HF report poorer quality of life compared to those with cardiac conditions 
other than HF (e.g., angina and hypertension) or those without HF.4-6  Symptom burden, 
from both physical (e.g., dyspnea and fatigue) and emotional (e.g., depressive symptoms) 
symptoms, contributes substantially to poorer quality of life.7-9  
Symptom status is one of the most important factors associated with adverse 
outcomes in patients with HF. In a longitudinal study, quality of life at three months was 
predicted by physical symptom status at baseline.10 Dyspnea was an independent 
predictor of increased risk for mortality, and fatigue independently predicted 
hospitalization due to HF exacerbation.11 Patients with highly variable daily symptom 
patterns of dyspnea and edema were at substantially greater risks for hospitalization for 
HF or mortality from HF.12 Thus, symptoms experienced by patients with HF should be 
properly assessed and managed to improve outcomes. 
It is imperative that clinicians and researchers use valid and reliable symptom 
instruments to capture symptom experiences accurately and to evaluate changes in 
symptoms. Most symptom instruments used in the HF population were originally 
designed for other populations, such as patients who had cancer (e.g., the Memorial 
Symptom Assessment Scale)13 or received palliative care (e.g., the Edmonton Symptom 
Assessment System).14 Although cancer and palliative care patients are chronically ill 
like patients with HF, the critical symptoms that need to be addressed may be different.  
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Some HF investigators have used items from HF-specific quality of life measures (i.e., 
the Minnesota Living with HF and the Kansas City Cardiomyopathy Questionnaire) to 
assess symptom status in patients with HF.15-17 There are a limited number of symptom 
instruments modified or designed for patients with HF; however, their psychometric 
properties have not been well demonstrated. A critical evaluation of the quality of 
symptom measures designed for and used in patients with HF is needed. 
Dyspnea is the most frequently assessed and reported symptom in acute care 
settings, although patients with HF also experience atypical symptoms, such as 
palpitations, hot flashes, and nausea/ vomiting, prior to seeking medical care.18-19 
Although typical symptoms reflecting congestion are important markers for healthcare 
providers to assess and manage HF, addressing only these typical symptoms may limit 
our ability to understand patients’ symptom experiences and provide comprehensive 
symptom management. It is critical to evaluate a full range of symptoms in patients with 
HF.  
Symptoms occur concurrently rather than in isolation. Patients with HF report 
multiple symptoms with an average of 15 physical and psychological symptoms,8 and the 
symptoms are associated with each other. For example, fatigue is associated with sleep 
difficulties, chest pain, weakness, and depressive symptoms.20-21 Dyspnea increases as 
edema becomes severe.22 Despite evidence that patients experience multiple symptoms 
simultaneously, few efforts to identify groups of symptoms (symptom clusters) and their 
impact on outcomes have been made in the HF population. 
The presence of multiple, co-occurring symptoms impedes the ability of patients 
with HF to seek medical assistance in a timely manner.23-24  Patients with HF have 
difficulty recognizing changes in any one or more symptoms. For example, about half of 
patients in one study reported that the recognition of critical symptoms (e.g., ankle 
swelling and dyspnea) reflecting HF exacerbation was challenging.25 Only 5% of patients 
realized that their worsening symptoms were caused by HF when they visited the 
hospital.19 Instead many patients associate their symptoms with other causes such as 
aging or other comorbid conditions.19, 26-27 Failure to distinguish between sources of the 
symptoms may lead to delays in seeking assistance and receiving timely management. 
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The main reason for hospitalization in patients with HF is worsening symptoms of 
HF. According to a situation-specific theory of HF self-care,28 self-care in HF is 
conceptualized as a naturalistic decision-making process, which consists of self-care 
maintenance to maintain physiological stability and self-care management to respond to 
altered symptom status. Self-care maintenance has two components, symptom monitoring 
and adherence to recommended regimens. Self-care management has three elements: 
recognizing symptoms, implementing treatment strategies, and evaluating the treatment 
strategies (Figure 1). By engaging in self-care maintenance and management, a delay in 
seeking care for worsening symptoms can be prevented. 
Regular symptom monitoring is essential for patients with HF to take action in 
response to changes in symptom status, which may ultimately shorten time to seeking 
care or prevent recurrent hospitalizations.29 One way to promote patients’ engagement in 
symptom monitoring behaviors is by providing a symptom diary where patients can keep 
track of their daily symptom changes. By keeping a symptom diary, patients may 
effectively detect and compare changes in symptom status without relying on recall. In 
one study, monitoring daily weight was associated with a decrease in one-year mortality 
rates and time to first hospitalization during a one-year follow-up in patients with HF. 
However, changes in weight alone do not always reflect worsening HF.30 A 
comprehensive symptom diary that includes weight and other HF symptoms and signs 
may substantially improve outcomes.  
The purpose of this dissertation was to develop and test a symptom diary with an 
education and counseling intervention in order to improve self-care and outcomes in 
patients with HF. Each chapter of this dissertation illustrates part of a journey to develop 
a preliminary program of research focused on improving symptom management and 
outcomes in patients with HF.  
In chapter two, results of a study to identify symptom clusters between men and 
women and determine the impact of symptom clusters on cardiac event-free survival are 
presented.17 Although patients with HF report experiencing multiple symptoms 
simultaneously, investigators tend to focus on individual symptoms and their impact on 
outcomes. It is important to examine whether there are symptom clusters (co-occurring 
symptom groups) in patients with HF and explore gender differences in symptom clusters 
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on outcomes. It is also necessary to explore gender differences in symptom clusters as 
symptom experiences between men and women are dissimilar.8, 31 To identify symptom 
clusters, hierarchical cluster analyses were conducted with seven symptoms that were 
commonly reported by patients with HF. Two identical symptom clusters were revealed 
in men and women: (1) a physical symptom cluster and (2) an emotional/ cognitive 
symptom cluster. Cox proportional hazards regression was used to determine whether the 
two symptom clusters predicted time to first cardiac event after adjusting for relevant 
demographic and clinical variables. 
In chapter three of this dissertation, a systematic, critical review of the literature is 
presented to examine the quality of existing symptom measures designed for and used in 
patients with HF. From a systemic search, five instruments were identified that met 
inclusion and exclusion criteria: M.D Anderson Symptom Index-HF; Memorial Symptom 
Assessment Scale-HF; HF Signs and Symptoms Checklist; HF Symptom Checklist; and 
HF Symptom Survey. These five symptom instruments were evaluated according to the 
following five evaluation categories adapted and modified from a previous study:32 (1) 
contents; (2) measuring scales; (3) psychometric properties; (4) completion process; and 
(5) information. 
In chapter four, results are presented from a study that was conducted to 
determine whether physical depressive symptoms altered the association between 
depressive symptoms and cardiac event-free survival in patients with HF. Selecting 
psychometrically sound instruments is important to evaluate the impact of symptoms.  
Depressive symptoms are a risk factor for deleterious outcomes in patients with HF. 
Popular depressive symptom instruments, such as the Beck Depression Inventory and the 
Patient Health Questionnaire-9, include physical depressive symptoms, such as fatigue, 
sleep disturbances, or changes in appetite. These physical depressive symptoms are 
reported in up to 84% of patients with HF regardless of depression status.8-9, 33 Patients 
who are symptomatic and in an advanced stage of HF are more likely to be judged to be 
depressed than patients who are asymptomatic.33-35  When depressive symptoms are 
measured with instruments including physical depressive symptom items, the depressive 
symptom scores may reflect the severity of HF rather than depressive symptoms. This, in 
turn, may inflate the association between depressive symptoms and outcomes in patients 
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with HF. It is critical to evaluate whether the use of depressive symptom measures, 
including physical symptoms, influence the relationship between depressive symptoms 
and outcomes. Thus, we compared the predictive abilities of a depressive symptom 
measure (the Patient Health Questionnaire-9) with and without physical depressive 
symptom items for cardiac event-free survival. 
In chapter five, the results of a study to examine the association between symptom 
monitoring behaviors and self-care management in patients with HF are presented. 
According to a situation-specific theory of HF self-care (Figure 1),28 it is suggested that 
symptom monitoring behaviors are essential for patients to adequately perform self-care 
management behaviors. However, the empirical evidence to support that adherence to 
symptom monitoring may result in appropriate self-care management is lacking. In this 
study, we examined the relationship between adherence to regular symptom monitoring 
and self-care management in patients with HF. 
Chapter six includes preliminary findings from a longitudinal, randomized, 
controlled pilot study to test the effect of a symptom diary with an education and 
counseling intervention on self-care maintenance, health-related quality of life, and 
prognosis in patients with HF at three months. Patients were invited to participate if they 
were diagnosed with HF and admitted to the hospital due to cardiovascular reasons (e.g., 
HF exacerbation and myocardial infarction). Baseline assessment was done within one 
month after the initial hospitalization and two additional follow-ups were made at one 
month and three months thereafter. 
A total of 44 patients were randomized into either the intervention or usual care 
groups. Patients in the intervention group received a symptom diary with education and 
counseling for 90 minutes, which was developed based on the HF Society of America 
guideline, at baseline.36 Additional biweekly booster sessions were done by the principal 
investigator via phone to discuss keeping the symptom diary, review important points 
from education and counseling sessions, and support patients. Heart failure events, which 
were defined as the composite of HF-related deaths and hospitalizations, and emergency 
department visits due to HF deterioration, were collected at three months via medical 
record reviews and interviews with patients or their families. Health-related quality of 
life, self-care maintenance, depressive symptoms, and New York Heart Association 
 
6 
functional class were measured at baseline, one month, and three months. The 
effectiveness of the intervention was evaluated by comparing group differences in 
changes in health-related quality of life and self-care maintenance, and the number of HF 
events for three months. 
In chapter seven, summary and conclusions from the findings of prior chapters are 
presented. Clinical implications and recommendations for future research are suggested. 
It is anticipated that findings from each chapter will contribute to comprehensive 
evaluation of the symptom experience of patients with HF by clinicians and researchers 
by suggesting the importance of assessing co-occurring symptoms (symptom clusters) 
and addressing issues related to existing symptom instruments. Results from this 
dissertation will translate into significant benefits for patients with HF and healthcare 
providers by providing evidence of the advantages of regular symptom monitoring in 
order to facilitate early identification of worsening symptoms of HF and initiation of 
timely responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kyoung Suk Lee 2012 
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Figure 1.1. A specific-situation theory of heart failure self-care 
 
 
Source: Riegel B, Dickson VV. A situation-specific theory of heart failure self-care. 
Journal of cardiovascular nursing 2008; 23:190-6 
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CHAPTER TWO  
Symptom clusters in Men and Women with Heart Failure and Their Impact on Event-
Free Survival 
Introduction 
Heart failure (HF) is a serious health problem worldwide. In the United States 
alone, HF afflicts around 5.7 million people.37 Physical and emotional symptoms are a 
defining feature of HF. Patients with HF have reported experiencing an average of 15 
physical and emotional symptoms.38 Occurrence of multiple symptoms adversely affect 
patient lives by increasing psychological distress and decreasing quality of life.10, 38-41  
To date, most researchers have focused on symptoms in isolation.42 However, 
patients with HF commonly experience more than one symptom at a time.38-41 The effect 
of multiple, concurrent symptoms on outcomes may be multiplicative.43-46 Patients with 
more symptoms or a greater degree of symptom burden have worse outcomes.38, 40, 44 
Fatigue severity mediated the association between pain and performance status in patients 
with cancer.44 Thus, the investigation of multiple symptoms as an interconnected 
experience is necessary to obtain a more complete picture of patient symptom 
experiences. 
The consideration of symptom clusters, defined as two or more interrelated 
symptoms occurring together provides a novel approach to symptom assessment and 
management.47 Patient’s ability to recognize a change in condition that requires urgent 
attention from their healthcare providers may be facilitated by knowledge about symptom 
clusters.48 Identifying the profiles of patients who are at risk for worse outcomes based on 
symptom clusters may support the development and delivery of effective, individualized 
strategies for specific groups of patients.48  
Gender may play a role in the HF symptom experience because HF 
characteristics, including etiology and prevalence of HF symptoms, differ between men 
and women.49 Women tend to present with more signs and symptoms related to HF (e.g., 
dyspnea, fatigue, lower extremity edema, third heart sound, jugular venous distension, 
and rales) than men.50-51 Some symptoms, such as fatigue, depression, and anxiety, are 
reported to be more prevalent and severe in women than men.38, 52-54 In addition, 
symptoms are an important determinant of outcomes, such as mortality and quality of 
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life.10, 38-40, 55-56 Given that women with HF tend to have worse outcomes compared to 
men,56-59 it is possible that symptom experiences are different between men and 
women.50, 60 Thus, comparison of symptoms between genders may provide valuable 
information for tailoring interventions for patients with HF.  
The purpose of this study was to compare symptom clusters between men and 
women with HF, differences in patient characteristics among symptom clusters, and the 
impact of these symptom clusters on outcomes. The specific aims were to: (1) determine 
whether different symptom clusters were present in men and women with HF, (2) 
compare patient characteristics of groups within symptom clusters, and (3) examine the 
impact of symptom clusters on event-free survival defined as time to first cardiac event 
(i.e., death, rehospitalization, or emergency department [ED] visit due to cardiac causes).   
Methods 
The data for this study were compiled from three prospective, longitudinal studies 
that had similar inclusion and exclusion criteria. Institutional Review Board approval was 
obtained for each study. Eligibility of patients who were referred to the investigators by 
nurses and physicians at each site was confirmed by the investigators or trained research 
nurses using medical record review. Patients who agreed to participate in the study 
provided written informed consent and completed the questionnaire packets during a visit 
to the General Clinical Research Center. Patients were followed for a median of 361 days 
to obtain cardiac event-free survival data. 
Patients 
A total of 331 patients were included in this study. Patients were recruited from 
HF outpatient clinics associated with six large community hospitals or academic medical 
centers in Kentucky, Georgia, and Indiana. Patients were included who: (1) had a 
confirmed diagnosis of HF with either preserved or non-preserved systolic function, (2) 
were receiving optimal medical therapy, (3) were able to read and speak English, and (4) 
had no obvious cognitive impairment that prevented completing the questionnaire packets 
and interview with research nurses. Patients were excluded if they had: (1) valvular heart 
disease as an etiology of their HF, (2) a myocardial infarction within the previous three 
months, (3) been referred for heart transplantation, or (4) major life-threatening 
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comorbidities such as end-stage renal or liver disease. Exclusion criteria for this study 
were selected because HF resulting from valvular heart disease may be correctable unlike 
HF from other etiologies. In addition, patients who had a myocardial infarction recently, 
been referred for heart transplantation or serious comorbidities are more likely to be 
hemodynamically unstable and have a shorter life expectancy.  
Measures 
Heart failure symptoms  
Symptoms were identified using the Minnesota Living with Heart Failure 
Questionnaire (MLHF),61 which consists of 21 items assessing health-related quality of 
life in patients with HF. The instrument contains the following eight items measuring 
distress from HF-related symptoms that are thought to influence health-related quality of 
life:10, 40, 62-63 edema, dyspnea, fatigue/increased need to rest, fatigue/low energy, sleep 
disturbances, worrying, feeling depressed, and cognitive problems (difficulty 
concentrating or remembering things). Patients rated each item on a scale from 0 (no 
distress) to 5 (very severe distress). In this study the internal consistency of these eight 
items was demonstrated by a Cronbach’s alpha of 0.89.  
Demographic and clinical characteristics.  
Demographic and clinical characteristics (e.g., age, gender, ethnicity, and body 
mass index [BMI]) were obtained using a demographic and clinical questionnaire. Total 
comorbidity scores were obtained from the Charlson Comorbidity Index.64 The scores of 
the Charlson Comorbidity Index were weighted by taking into account the number and 
seriousness of comorbid illnesses. New York Heart Association (NYHA) functional 
classification was determined by trained research nurses via in-depth structured patient 
interviews. 
Cardiac event-free survival.  
Cardiac event-free survival was defined as time to first cardiac event which 
included death, rehospitalization, or ED visit due to cardiac reasons. The data were 
obtained by monthly follow-up calls to patients or family and by administrative review of 
medical records and public death records.  
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Statistical Analyses  
Data were analyzed using SAS (version 9.1, SAS Institute Inc, Cary, NC). 
Descriptive statistics including frequency distributions, means, standard deviations, and 
ranges were used to describe the demographic and clinical characteristics of patients.  
Cluster analysis was used to identify symptom clusters because this technique 
maximizes the homogeneity of variables within clusters while simultaneously 
maximizing the heterogeneity between clusters.65 We used the hierarchical cluster 
agglomerative approach which begins with treating each variable as a separate cluster and 
then combines the variables into consecutively larger clusters based on their similarity. 
The Euclidean distance was used to measure the similarity of variables. Proximity 
between groups of variables was measured using Ward’s method by which clusters were 
joined by minimizing the total within-cluster error sum of squares. Ward’s method was 
chosen because it is sensitive to outliers and effective when identifying clusters compared 
to other inter-group proximity measures.66  
The resulting clusters were pictorialized with dendrograms, which illustrate the 
proximity of variables to each other. Semi-partial R-squared scores were used to 
determine the degree of homogeneity of variables within the clusters, with larger values 
reflecting less similarity between clusters. To decide the optimal number of clusters we 
used dendrograms, the pseudo-F statistic, and the pseudo-T squared statistic.66 To 
demonstrate the validity of the identified number of clusters, principal component 
analysis was conducted and the first and second principal component scores were 
plotted.67   
Based on the identified symptom clusters, patients were divided in groups by the 
median split of total scores of each symptom cluster, which were calculated by summing 
distress scores of symptoms in each cluster. Analysis of variance (ANOVA) or the chi-
square test was used to compare differences in demographic and clinical characteristics 
among four patient groups (i.e., low distress, physical distress, emotional/cognitive 
distress, and high distress). Post hoc analysis was done using the Bonferroni adjustment. 
Hierarchical Cox proportional hazards regression was used to determine whether total 
scores of symptom distress within symptom clusters predicted time to first cardiac event 
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(i.e., death, rehospitalization, or ED visit due to cardiac reasons) after controlling for age, 
gender, total comorbidity scores, BMI, and NYHA functional class. 
Results 
Sample Characteristics 
The mean age of patients was 61years with a range of 24 to 87 years (Table 1). 
Patients were predominately male, Caucasian, married or cohabitating, and obese. The 
majority of patients had an ischemic HF etiology, and were in NYHA functional classes 
III and IV. A greater percentage of women were non-Caucasian (i.e., African-American 
and Hispanics), and had non-ischemic HF etiology (e.g., idiopathic and hypertension) 
than men (p<0.05).  
Symptom distress scores from each individual symptom are illustrated in Table 2. 
All patients reported that among physical symptoms fatigue/low energy was the most 
distressful and edema the least (mean ± S.D 3.0 ±1.7 vs. 1.2 ± 1.5), while among 
emotional/cognitive symptoms, worrying was the most distressful and feeling depressed 
the least (mean ± S.D 1.7 ±1.8 vs. 1.5 ± 1.5). Women reported significantly higher levels 
of distress from fatigue/ increased need to rest, sleep disturbances, and feeling depressed 
than men, while all other symptoms were rated similarly by men and women. 
Symptom Clusters  
Three identical clusters were identified in men and women. The first cluster 
labeled the physical symptom cluster included dyspnea, fatigue/increased need to rest, 
fatigue/low energy, and sleep disturbances. The second cluster labeled the 
emotional/cognitive symptom cluster, included worrying, feeling depressed, and 
cognitive problems. Edema formed a third, single symptom cluster. The dendrograms and 
the pseudo-F and pseudo-T squared statistics indicated that three clusters were the 
optimal solution, which was also confirmed by the principal component analysis (Figures 
1 and 2). Because the definition of a symptom cluster is two or more symptoms that 
occur simultaneously, edema was excluded from further analyses. Also, because gender 
differences in symptom clusters were not found, the whole sample was used for further 
analyses. 
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Characteristics of Symptom Cluster Groups  
Patients were divided into four groups based on the median split of total symptom 
distress scores of the physical and emotional/cognitive symptom clusters. The “low 
distress” group included patients with low distress in both physical and 
emotional/cognitive symptom clusters. The “physical distress” group included patients 
with high distress scores in the physical symptom cluster and low distress scores in the 
emotional/cognitive symptom cluster. The “emotional/cognitive distress” group included 
patients with high distress scores in the emotional/cognitive symptom cluster and low 
distress scores in the physical symptom cluster. The “high distress” group included 
patients with high distress scores in both physical and emotional/cognitive symptom 
clusters.  
Comparisons of characteristics among the four groups are summarized in Table 3. 
Patients in the physical distress and high distress groups consisted primarily of females 
and those in NYHA functional class III and IV. Patients in the emotional/cognitive 
distress and high distress groups were younger than patients in the low distress and 
physical distress groups. Patients in the high distress group had a greater comorbidity 
burden than those in the other three groups. Fewer beta blockers, angiotensin-converting 
enzyme inhibitors (ACE I), or angiotensin-receptor blockers (ARB) were taken by 
patients in the physical distress group compared to the other three groups.  
Prediction of Cardiac Event-Free Survival   
During a median follow-up period of 361 days, there were 82 cardiac events 
(Table 4): death 2% (2/82); hospitalization 81% (66/82); and ED visit 17% (14/82). The 
cardiac event rates of the four groups were 17.5% (22/126) in the low distress group, 
16.7% (6/36) in the physical distress group, 32.6% (15/46) in the emotional/cognitive 
distress group, and 31.7% (39/123) in the high distress group. The results of the 
multivariate hierarchical Cox regression analysis for symptom clusters are summarized in 
Table 5. Because the total symptom distress scores in the physical and 
emotional/cognitive symptom clusters were significantly correlated (r=0.644, p<0.01), 
the interaction effect of the two symptom clusters was included in the analysis. The total 
symptom distress score in the emotional/cognitive symptom cluster, but not the physical 
symptom cluster, was an independent predictor of cardiac event-free survival after 
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adjusting for age, gender, total comorbidity scores, BMI, and NYHA functional class 
(p=0.007). Every one unit increment in distress scores in the emotional/cognitive 
symptom cluster was associated with an 18% increase in the risk for a cardiac event.  
The four groups were entered as categorical variables into the multivariate 
hierarchical Cox regression to determine which group had a higher risk for a cardiac 
event. Figure 3 depicts the survival curves of the four groups after controlling for age, 
gender, total comorbidity score, BMI, and NYHA functional class. Patients in the 
emotional/cognitive distress (hazard ratio [HR]: 2.40, 95% confidence interval [CI] 1.31-
4.41) and high distress groups (HR: 2.02, 95% CI 1.03-3.95) had a higher risk for a 
cardiac event compared to those in the low distress group. However, there were no 
differences in time to first cardiac event between patients in the physical distress and low 
distress groups. 
Discussion 
This was the first study to compare symptom clusters between genders in patients 
with HF and to determine whether symptom clusters predicted cardiac event-free 
survival. Contrary to what we hypothesized based on prior research, gender differences in 
HF symptom clusters were not found. Between the two symptom clusters, only the 
emotional/cognitive symptom cluster predicted higher risk for a cardiac event. 
The relationships among individual symptoms and outcomes in patients with HF 
have been reported in previous studies.55, 68-73 For example, in the study of Ekman and 
colleagues dyspnea severity was a predictor of increased death and all-cause 
rehospitalization and fatigue severity was a predictor of rehospitalization due to HF 
exacerbation.55 Heart failure patients with depressive symptoms have also been reported 
to have up to a two-fold greater risk for death (HR=1.08-2.25).68, 70-71 While these results 
are informative, they do not provide a full understanding of the relationship between 
symptoms and outcomes of patients with HF given that patients commonly experience 
multiple symptoms concurrently.  
There are data suggesting that the presence of co-occurring symptoms may 
convey a higher risk for negative outcomes43-45 that might be only identifiable when 
symptoms are considered together. The coexistence of anxiety and depressive symptoms 
in patients with coronary heart disease was associated with a higher risk for mortality 
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when compared with the presence of either symptom alone.43 Advanced cancer patients 
with concurrent four symptoms were nine times more likely to die compared to those 
with one symptom.45 Thus, exploring symptom clusters appears to be important for 
accurate risk assessment of patients with HF. 
We demonstrated a greater risk for shorter cardiac event-free survival time in 
patients with higher distress scores from the emotional/cognitive symptom cluster than 
the physical symptom cluster. A potential reason for this finding is that healthcare 
providers and patients often focus more on physical than psychological symptoms. 
Because the primary reasons for seeking health care are usually related to physical 
manifestations of HF, healthcare providers tend to treat physical symptoms and not 
explore psychological factors that might be an underlying cause of HF events.74 For 
example, the ACC/AHA guideline for diagnosis and management of HF address physical 
signs and symptoms, but not patient emotional or cognitive symptoms.75 Consequently, 
the assessment of emotional or cognitive symptom status might not often occur and 
subsequently not be managed appropriately.  
The lack of an impact of physical symptom cluster on cardiac event-free survival 
may also be explained by the association between self-care and symptoms experienced by 
patients with HF. Heart failure patients whose symptoms are severe enough to impair 
daily activities have a better understanding of the importance of self-care.76 Severe 
physical symptoms may also motivate patients to perform better self-care to prevent 
worsening symptoms. On the other hand, the negative impact of individual 
emotional/cognitive symptoms on engaging in self-care was reported in previous 
studies:77-82 Patients who are depressed, anxious, or cognitively impaired tend to 
experience greater difficulty with and fewer benefits to the performance of self-care (e.g., 
taking medications as directed and monitoring symptoms regularly), difficulty 
remembering complex recommendations on medication, diet, or symptom monitoring, 
and have less ability to accurately interpret the changes in symptom status.  
There is evidence that patients with depressive symptom often experience 
cognitive impairment simultaneously. Brain structural changes that involved in emotional 
and cognitive functions (e.g., hippocampus and caudate nuclei) were observed in patients 
with HF,83 which may explain why they occur as a cluster. Other evidence to support this 
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conclusion includes the study by Alves and colleagues84 in which depressive symptom 
scores predicted overall cognitive function in patients with HF. Cognitive function was 
improved by eight-week antidepressant treatment in HF patients with major depressive 
disorder.84 Our data suggest that coexistence of both symptoms might magnify the 
detrimental impact of each symptom and worsen outcomes more than the presence of a 
single symptom. Thus, it is important to monitor and manage symptoms in cluster in 
patients with HF.  
In the cluster analysis, edema was not included in either symptom cluster for 
either gender. This may be related to lower distress scores for edema compared to the 
other symptoms in this study. Given that clusters were constructed by minimizing the 
heterogeneity within clusters, the lower distress score for edema led to greater 
dissimilarity with other symptoms. Patients who experience edema commonly delay 
contacting their healthcare provider before acute cardiac decompensation;85-86 this may 
occur because they are less likely to experience distress from edema. 
Information about patient characteristics may be of value for healthcare providers 
to develop and deliver efficacious strategies, such as risk assessment, that may help to 
prevent potential adverse outcomes. Thus, we examined characteristics of patients 
according to symptom cluster groups. There were more women in the “physical distress” 
and “high distress” groups in which patients experienced more distress from physical 
symptoms. Similar results were reported in previous studies in which women experienced 
more physical impairment than men.59, 87-88 Patients were primarily younger in the “high 
distress” and “emotional/cognitive distress” groups, which suggests that younger patients 
with HF experience greater distress from the emotional/cognitive symptom cluster 
regardless of the distress associated with the physical symptom cluster. This finding is in 
line with previous research reporting better physical and worse emotional status in 
younger patients with HF.10, 71, 73, 89 Given that greater distress from the 
emotional/cognitive symptom cluster was associated with earlier cardiac events in this 
study, healthcare providers should focus attention on younger patients who have poor 
psychological status regardless of their physical status. 
There were several limitations of this study. First, the results of this study may not 
be generalizable to all patients with HF, particularly older patients and ethnic groups 
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other than Caucasian. Second, the MLHF was used as the measure of symptom distress. 
This instrument is primarily a measure of health-related quality of life. However, given 
the demonstrated reliability and validity of the MLHF, using symptom data from this 
instrument was a scientifically sound approach to meet the aims of this study. Although 
patients with HF experience a wide range of symptoms, we only evaluated seven 
symptoms. The limited number of symptoms included might not fully capture patient 
symptom experiences. However, the symptoms included in this study are reported most 
frequently by patients with HF.38-40 Third, we assessed only symptom distress levels. 
Additional symptom dimensions including frequency and intensity may also need to be 
considered. In cancer patients, symptom distress was relatively persistent over time 
compared to intensity90 and baseline symptom distress predicted distress levels three and 
six months later.91 Thus, symptom distress might be the best predictor of long-term 
outcomes like survival.  
Conclusions 
In this study we demonstrated that symptoms occur in clusters rather than in 
isolation. These findings provide a new perspective on symptom assessment and 
management in patients with HF by highlighting the importance of symptoms clusters. 
Identifying symptom clusters may guide and support the development of more 
comprehensive interventions.48, 92 Teaching patients about symptom clusters might also 
improve symptom recognition by promoting greater patient self-awareness. If patients 
know that symptoms occur in clusters, awareness of one symptom may trigger self-
assessment for presence of additional symptoms, which might facilitate health care-
seeking behaviors for changes in symptom status in a timely manner. Thus, focusing on 
symptom clusters may lead to better patient outcomes. 
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Table 2.1. Sample characteristics (N=331) 
Notes. ‡ Higher scores indicate greater distress 
HF: heart failure; NYHA: New York Heart Association functional class; ACE I: angiotensin-
converting enzyme inhibitors; ARB: angiotensin receptor blocking agents 
Characteristics 
Total Male  (n=216) 
Female 
(n=115) p-value 
Mean (± S.D) or N (%) 
Age, years  61 (± 11) 60 (± 11) 62 (±11) 0.233 
Ethnicity     <0.001 
Caucasian  269 (81%) 188 (87%) 81 (70%)  
Marital status    <0.001 
Married/ cohabitate 181 (55%) 141 (65%)  40 (35%)  
Single/divorced/ widowed 150 (45%) 75 (35%) 75 (65%)  
Ischemic etiology of HF 179 (54%) 137 (65%) 42 (38%) <0.001 
NYHA class     0.203 
I/II 128 (39%) 91 (42%) 37 (32%)  
III 145 (44%) 90 (42%) 55 (48%)  
IV 58 (18%) 35 (16%) 23 (20%)  
Body mass index (kg/m2) 32 (± 7) 31 (± 7) 32 (± 8) 0.548 
Charlson comorbidity index  3.4 (± 2.0) 3.4 (± 2.0) 3.4 (± 2.0) 0.837 
ACE I or ARB  278 (84%) 186 (86%) 92 (80%) 0.078 
Beta blocker 287 (87%) 185 (86%) 102 (89%) 0.630 
Total scores of physical 
symptom cluster‡ 10 (± 6) 10 (± 6) 12 (± 6) 0.004 
Total scores of emotional/ 
cognitive cluster‡ 5 (± 5) 5 (± 4) 5 (± 5) 0.453 
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Table 2.2. Symptom distress scores between men and women (N=331) 
 Male (n=216) Female (n=115) p-value 
Edema 1.1 (± 1.5) 1.4 (± 1.6) 0.130 
Dyspnea 2.7 (± 1.8) 2.9 (± 1.7) 0.747 
Fatigue/increased need to rest 2.0 (± 1.7) 2.8 (± 1.8) 0.011 
Fatigue/low energy 2.9 (± 1.7) 3.3 (± 1.6) 0.150 
Sleep disturbances 2.0 (± 1.8) 2.5 (± 1.9) 0.010 
Worrying 1.7 (± 1.7) 1.7 (± 1.9) 0.305 
Feeling depressed 1.4 (± 1.6) 1.6 (± 1.9) 0.021 
Cognitive problems 1.6 (± 1.7) 1.8 (± 1.9) 0.213 
Values are mean (± S.D)  
 
20 
Table 2.3. Characteristics of patients in symptom cluster groups (N=331) 
 Low distress
both 
Physical 
distress 
Emotional/ 
cognitive 
distress 
High distress 
both  
 n= 126 n= 36 n= 46 n= 123 p-value 
Age, years  64 (± 12)a 66 (± 8)a 58 (± 12)b 58 (± 10)b <0.001 
Female  35 (28%) 18 (50%) 11 (24%) 51 (42%) 0.011 
Ethnicity     0.793 
Caucasian  103 (82%) 29 (81%) 39 (85%) 98 (80%)  
Marital status     0.020 
Married/ 
cohabitate 68 (54%) 12 (33%) 31 (67%) 70 (57%) 
 
Single/ divorced/ 
widowed 58 (46%) 24 (67%) 15 (33%) 53 (43%) 
Ischemic etiology of 
HF 69 (55%) 21 (58%) 29 (63%) 60 (49%) 0.451 
NYHA class      <0.001 
   I/II 74 (59%)a 5 (14%)a 24 (52%)b 25 (20%)a 
    III 37 (29%)a 22 (61%)b 20 (44%)b 66 (54%)b 
   IV 15 (12%)b 9 (25%)b 2 (4%)a 32 (26%)a 
Body mass index 
(kg/m2) 30 (± 8) 33 (± 7) 32 (± 7) 32 (± 7) 0.276 
Charlson comorbidity 
index  3.1 (± 1.7)
a 3.5 (± 1.6) 3.0 (± 1.5) 3.9 (± 2.2)b 0.004 
ACE I or ARB  113 (90%)a 22 (61%)b 41 (89%)a 102 (83%)a <0.001 
Beta blocker 116 (92%)a 26 (72%)b 37 (80%)a 108 (88%)a 0.009 
Total scores of 
physical symptom 
cluster 
5 (± 3)a 14 (± 3)b 7 (± 2)a 16 (± 3)b <0.001 
Total scores of 
emotional/ cognitive 
symptom cluster 
1 (± 1)a 1 (± 1)a 6 (± 2)b 10 (± 3)b <0.001 
Notes. Values are mean (± S.D) or N (%)  
Low distress: low distress scores in both symptom clusters; Physical distress: high distress scores 
in physical symptom cluster; Emotional/cognitive distress: high distress scores in 
emotional/cognitive symptom cluster; and High distress: high distress scores in both symptom 
clusters 
HF: heart failure; NYHA: New York Heart Association functional class; ACE I: angiotensin-
converting enzyme inhibitors; ARB: angiotensin receptor blocking agents 
Groups with different superscripts are significantly different from each other. Groups without 
superscript do not differ from one another. 
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Table 2.4. Cardiac events in symptom cluster groups (N=82) 
 Low distress 
both 
Physical 
distress high 
Emotional/ 
cognitive 
distress high 
High distress 
both 
 n= 22 n= 6 n= 15 n= 39 
Death 2 (2%) 0 (0%) 0 (0%) 0 (0%) 
Rehospitalization 17 (13%) 5 (14%) 11 (24%) 33 (27%) 
Emergency department visit 3 (2%) 1 (3%) 4 (9%) 6 (5%) 
Notes. Values are N (%) 
Low distress: low distress scores in both symptom clusters; Physical distress: high distress scores 
in physical symptom cluster; Emotional/cognitive distress: high distress scores in 
emotional/cognitive symptom cluster; and High distress: high distress scores in both symptom 
clusters 
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Table 2.5. Multivariate Cox regression analysis for symptom clusters (N=331) 
 Hazard Ratio p-value 
95% Confidence 
Interval 
Age 0.985 0.180 0.96-1.01 
Female 1.633 0.059 0.98-2.72 
NYHA    
   NYHA I/II 1.000   
   NYHA III 1.005 0.985 0.60-1.69 
   NYHA IV 0.800 0.542 0.39-1.64 
Charlson Comorbidity Index 1.217 0.003 1.07-1.39 
Body mass index (kg/m2) 0.959 0.020 0.93-0.99 
Emotional/Cognitive Symptom Cluster Score 1.184 0.021 1.03-1.37 
Physical Symptom Cluster Score 1.039 0.285 0.97-1.12 
Interaction between Emotional/Cognitive and 
Physical Symptom Cluster 0.990 0.052 0.98-1.00 
Total model p-value=0.007 
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Figure 2.1. Symptom cluster dendrogram for men 
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Figure 2.2. Symptom cluster dendrogram for women 
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Figure 2.3. Cardiac event-free survival by four symptom cluster groups 
 
 
 
 
 
 
 
 
Note. Groups with different superscripts are significantly different from each other. Groups 
without superscript do not differ from one another.  
 
Low distress: low distress scores in both symptom clusters; Physical distress: high distress scores 
in physical symptom cluster; Emotional/cognitive distress: high distress scores in 
emotional/cognitive symptom cluster; and High distress: high distress scores in both symptom 
clusters 
 
 
 
Model p-value=0.02 
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CHAPTER THREE 
Heart Failure Symptom Measures: systematic review 
Introduction 
Heart failure (HF) is a progressive, irreversible clinical syndrome, characterized 
by a variety of symptoms.16 Patients with HF report an average of nine physical 
symptoms even when they are not experiencing an exacerbation.33 Dyspnea and fatigue, 
the most prevalent HF symptoms, are experienced by more than half and up to 94% of all 
patients with HF, respectively.8, 33, 50, 93 The presence of multiple symptoms negatively 
affects functional status, quality of life, and survival.8, 17, 93-94 Thus, it is essential to 
provide effective symptom assessment and management in the HF population.  
One of the primary goals of HF management is reducing patient symptom burden. 
To achieve this goal, conducting a systematic symptom assessment is essential. It is 
important that healthcare providers inquire not only about the most common physical 
symptoms of HF such as dyspnea, but also psychological symptoms such as depressive 
symptoms. Comprehensive evaluation of symptoms allows healthcare providers to (1) 
help reduce symptom burden, a focus important to patients and (2) assess the 
effectiveness of interventions to improve symptoms. However, there are few symptom 
instruments developed for patients with HF that measure the full range of symptoms 
experienced by patients. Although the symptom experience is multi-dimensional, 
meaning that it includes not only presence or absence of symptoms, but frequency, 
severity, and distress related to symptoms, some instruments are designed to evaluate 
only one aspect of the symptom experience. Thus, in order to accurately assess the 
symptom experience in patients with HF, it is critical to evaluate commonly used 
instruments.  
The purpose of this paper is to provide a critical review and analysis of self-
reported symptom measures designed for and used in patients with HF. The specific aims 
of this paper are to (1) provide a conceptual definition of symptoms; (2) identify 
symptom instruments designed for HF patients; and (3) evaluate their quality with five 
criteria (i.e., content, measuring scale, psychometric properties, completion process, and 
information). 
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Conceptual Definitions of Symptoms 
According to the Oxford English Dictionary, a symptom is defined as “bodily or 
mental phenomenon, circumstance, or change of condition arising from and 
accompanying a disease or affliction, and constituting an indication or evidence of it.”95 
This definition is distinguished from that of a sign, which is “objective evidence or 
indication of disease.”96 Researchers commonly conceptualize symptoms as subjective 
phenomena indicating perceived alterations in normal function (e.g., biopsychosocial 
aspects, sensations, or cognition).97-98 Symptoms are not merely the reflection of 
functional or structural abnormalities in body organs and systems. Rather, they are 
integrated and meaningful experiences that reflect the reality of the person experiencing 
them in the context of his or her cultural and personal situation.99 Thus, symptoms change 
over time within a person and are experienced in a variety of ways among those with the 
same symptoms.100 
Symptoms are multi-dimensional. Lenz and colleagues46 suggested four 
dimensions of symptoms – quality, timing, intensity, and distress. Quality refers to 
symptom characteristics (e.g., throbbing or pounding pain), the location of a given 
sensation, and response to a particular intervention. Timing is the frequency and duration 
of symptoms. Intensity refers to symptom severity and is commonly used in clinical and 
research settings due to its relatively easy quantification.46 Distress refers to the extent to 
which the person is bothered by a symptom. Although symptom occurrence, intensity, 
and distress are strongly inter-correlated, they are unique components of the symptom 
experience.101  
People commonly experience multiple symptoms.46, 98 The impact of co-occurring 
symptoms is multiplicative rather than additive. The coexistence of four symptoms in 
advanced cancer patients was associated with nine times higher risk for death compared 
to the presence of one symptom.45 Therefore, symptoms are subjective, experiential, and 
multiplicative if several symptoms occur simultaneously.  
Methods 
A systematic search using the PubMed and Cumulative Index of Nursing and 
Allied Health Literature (CINAHL) databases (August 1978 to July 2011) was 
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undertaken. Search terms were selected by scanning search strategies of a systematic 
review on a similar topic32 and examining index terms (e.g., subject headings). 
Combinations of key words and subject headings were used for the electronic database 
search. The key words searched in the two databases were (1) (Heart failure) AND (Signs 
and Symptoms) AND (Scale OR Instrument OR Checklist OR Inventory) AND 
(Evaluation OR Assessment OR Measurement OR Rating) AND (Distress OR Severity 
OR Frequency OR Prevalence); and (2) (Heart failure) AND (Signs and Symptoms) 
AND (Reliability OR Validity OR Psychometric). Because CINAHL yielded few 
citations, a new search using index terms was used: (Heart Failure-subheading: 
Symptoms) AND (Major heading: Symptoms OR Quality of life OR Self-care OR 
Palliative care OR Cardiac patients). References lists and bibliographies of all pertinent 
articles identified by online database searches were searched.  
The search was limited to journal articles and proceedings which were published 
in English. Instruments were included in the review if they were primarily designed or 
modified for patients with HF to measure multiple symptoms (> two symptoms). 
Exclusion criteria included quality of life instruments or their modified versions; single-
symptom item instruments; instruments measuring symptom perception (awareness) or 
functional status rather than symptoms; or diary-type instruments.  
Instrument Evaluation 
Instruments were evaluated based on five criteria, which we modified according 
to the criteria developed by Kirkova and colleagues32 to rate the quality of the instrument. 
Because Kirkova and colleagues did not explicitly describe how to rate each category of 
an ideal instrument, we modified the original five evaluation categories with specific 
evaluation criteria for each category (Table 1). The five evaluation categories were: (1) 
contents (i.e., comprehensive assessment of symptoms included in the instruments); (2) 
measuring scale (i.e., simplicity and ease of use by subjects and suitability in clinical and 
research purposes); (3) psychometric properties (i.e., precision and accuracy); (4) 
completion process (i.e., burden of the instrument completion); and (5) information (i.e., 
usefulness to facilitate effective symptom management).  
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Results 
The search strategies yielded 323 articles and proceedings. Of those, 13 articles8, 
102-111 and proceedings112-113 met the inclusion and exclusion criteria for this review. Of 
the 13 articles and proceedings found, seven symptom measures developed for patients 
with HF that included three or more symptoms were identified (Table 2). However, the 
EuroHeart Failure Survey-Symptom110 and the modified version of the Cardiac Symptom 
Survey111 were excluded because information on these instruments (e.g.,  psychometric 
properties or  how it was developed) was not available in the literature or from the 
corresponding authors. An article,103 in which the Memorial Symptom Assessment Scale-
HF (MSAS-HF) was used, was also excluded in this review. Although the authors 
claimed to use the MSAS-HF, only 10 out of 32 symptoms were used and patients were 
asked to report their symptom experience over the two weeks instead of seven days, 
which was the timeframe used in the MSAS-HF.  
Of the five symptom instruments, three were modified based on symptom 
measures developed for patients with cancer or cardiac surgery (i.e., the HF Symptom 
Survey112 from the Cardiac Symptom Scale, the M.D. Anderson Symptom Inventory-HF 
[MDASI-HF]108 from the M.D. Anderson Symptom Inventory, and MSAS-HF113 from 
the MSAS).  
The symptom measures reviewed in this paper included signs (e.g., weight gain 
and diarrhea) along with symptoms, despite the fact that the definitions of signs, defined 
as “objective evidence or indication of disease”96 and symptoms, defined as “bodily or 
mental phenomenon, circumstance, or change of condition arising from and 
accompanying a disease or affliction, and constituting an indication or evidence of it”95 
are different and clearly describe distinct phenomenon.  However, it was impossible to 
separate signs out from the measures and evaluate them. Thus, we reviewed symptom 
measures as they were.  
Contents  
The five instruments varied in the number of symptoms/ signs assessed (13-32 
symptoms/ signs). Many symptoms overlapped, yet were not always included in all five 
measures (Table 3). The HF Signs and Symptoms Checklist,107 the MDASI-HF,108 and 
MSAS-HF113 included not only typical HF symptoms related to fluid overload (e.g., 
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fatigue and swelling) but also atypical symptoms (e.g., dry mouth and diarrhea). Three of 
the five instruments contained both physical and psychological symptoms, but the HF 
Symptom Checklist102 and the HF Signs and Symptoms Checklist107 did not.  Orthopnea, 
paroxysmal nocturnal dyspnea, edema, and coughing were addressed in all five 
instruments. Psychological symptoms were not included in the HF Signs and Symptoms 
Checklist107 and the HF Symptom Checklist102, and fewer psychological than physical 
symptoms were included (2-5 psychological symptoms).The most frequently included 
psychological symptom was feeling depressed.  
Symptoms were described with different descriptors. Coughing was further 
specified as “worsening cough,”112  “nighttime cough,”108 “dry and hacking cough,”102 
and “severe cough -keeping awake at night or chest hurts when coughing.”107 Symptoms 
items in the HF Signs and Symptoms Checklist were more descriptive than other 
instruments. For example, weight gain was also further specified as “greater than 2 
pounds in a day or 5 pounds in a week” in the HF Signs and Symptoms Checklist,107 
while general terms were used in other measures such as “weight gain” in the MSAS-
HF.113  
Multiple symptom dimensions (e.g., frequency and severity) were addressed in 
three measures (i.e., the HF Symptom Survey, MDASI-HF, and MSAS-HF), while only 
presence or absence of symptoms was assessed in the HF Symptom Checklist102 and the 
HF Signs and Symptoms Checklist.107  Symptom frequency was the least frequently 
reported while severity and distress (or interference) were the most frequently included. 
There were no symptom measures that inquired about co-occurring symptoms to examine 
the presence of symptom clusters.    
Measuring Scale 
Reading levels of the instruments were not explicitly addressed. However, the 
authors who developed the HF Signs and Symptoms Checklist and the MDASI-HF 
mentioned their efforts to simplify wording of items in order to increase patients’ 
understanding.107-108  
Depending on the purpose of symptom instruments (e.g., daily symptom or 
intermittent symptom assessment), patients were asked to recall their symptom 
experience within a certain time period. Timeframes varied from “during last 24 hours” 
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108 to “during previous two weeks,”102 although most instruments measured symptoms 
that had been experienced over seven days.  
With the exception of the two instruments (i.e., the HF Signs and Symptoms 
Checklist and HF Symptom Checklist) measuring the presence or absence of the 
symptoms (yes or no),102, 107 numeric ratings were used in three instruments (i.e., the HF 
Symptom Survey, MDASI-HF, and MSAS-HF). 108, 112-113 In the HF Symptom Survey, 
patients were asked to write down the appropriate numeric values to indicate their 
symptom scores from 0 to 10, while response options in the MSAS-HF and the MDASI-
HF were laid out and patients circled their rating. Each numeric point in the scale was 
labeled with adjectives (e.g., mild and severe) in the MSAS-HF, while adjectives were 
given at the anchors in the MDASI-HF.  
Information about completion rates was unavailable except for the HF Symptom 
Survey. In a study using the HF Symptom Survey, 5% of patients (7/139) did not fill out 
all symptom dimensions of each symptom or responded in a contradictory manner (e.g., 
despite indicating not having a symptom, nonzero ratings of other symptom dimensions 
for the same symptom were given).104 No more than 3% of responses per symptom were 
missing.104  
Scores on each dimension (e.g., severity and frequency) were commonly derived 
by summing and/or averaging scores of each symptom. However, to compute total 
distress scores in the MSAS-HF its original distress scores, which ranged from 0-4, were 
rescaled with a 0.8 increase.8 Composite scores of all the dimensions scored were formed 
in the MSAS-HF and the MDASI-HF.  The total burden score in the MSAS-HF was 
determined by averaging scores in each dimension of symptoms (frequency, severity, and 
distress).8 An overall symptom distress score in the MDASI-HF was computed based on 
the mean scores of six symptom interference items (i.e., how have your symptoms 
interfered with your life).108 There were subscales for HF-specific symptoms in the 
MSAS-HF and the MDASI-HF that were scored by averaging scores of HF relevant 
symptoms, such as swelling, coughing, and palpitations.  
The five symptom measures covered 13 to 32 symptoms/ signs, but the number of 
items that patients answered was often larger than the number of symptoms included in 
the measure. This occurs because multiple symptom dimensions were assessed with each 
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symptom item. For example, in the HF Symptom Survey, in which 14 symptoms were 
included and four dimensions were assessed in each symptom, patients answered a total 
of 56 items. 
Psychometric Properties 
Reliability. Reliability is the indicator of the extent to which measurements yield 
similar results on repeated testing with a population of individuals or groups.114 The 
reliability coefficient is estimated based on subject variability and measurement error and 
can range from 0 to 1, with 1 indicating perfect reliability without measurement errors. 
There are two types of reliability measures: internal consistency and stability. Internal 
consistency reflects the correlations among all the items in the measures, which can be 
tested with Cronbach’s alpha or split halves. Stability represents the reproducibility of a 
measure administered at different times, which can be expressed with inter-observer 
reliability or test-retest reliability.114 Acceptable reliability coefficients are greater than 
0.8 for internal consistency and greater than 0.5 for stability.114 Internal consistency was 
reported in all instruments except for the HF Signs and Symptoms Checklist. Stability 
was not reported in any of the five symptom instruments reviewed in this paper. 
The HF Symptom Survey. Good internal consistency across the four symptom 
dimensions (frequency, severity, interference with physical activity, and interference with 
enjoyment of life) was observed with Cronbach’s alphas of 0.80-0.88.112 
The HF Symptom Checklist. The Cronbach’s alpha coefficient was 0.68,102, 105-106 
which is lower than the desirable values of the internal consistency (Cronbach’s alpha 
coefficient  ≥0.8).114 
The M.D. Anderson Symptom Inventory-HF. Good reliability was observed for the 
13 MDASI-HF core symptoms, eight HF symptoms, and six interference items with 
Cronbach’s alphas of 0.89, 0.83, and 0.92, respectively.108 
The Memorial Symptom Assessment Scale-HF. Internal consistency reliability of 
burden scores in each subscale was examined using Cronbach’s alphas, which were 0.80 
-0.87 for the physical symptom subscale; 0.83- 0.91 for the psychological symptom 
subscale; and 0.73- 0.85 for the HF symptom subscale.8, 113  
Validity. Validity is the degree to which instruments measure what they purport to 
measure.115 There are several types of validity testing, which are content, criterion 
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(concurrent and predictive), and construct (e.g., convergent and discriminant, 
discriminative, and factor structure analysis) validity.115 Content validity addresses how 
well the items cover the construct of interest, which is determined based on the 
judgments of experts in the field. Criterion validity provides evidence about how well 
scores on a measure are correlated with other measures that have same or highly related 
constructs and has been used and accepted in the field as a gold standard. Construct 
validity is a judgment based on the accumulation of evidence demonstrating the 
relationship between the measure being evaluated and the variables known to be related 
or theoretically related to the construct measured by the instrument.115  
The HF Symptom Survey. The 14 symptoms were identified by literature review. 
A HF expert panel consisting of four nurses examined its content validity.104 Criterion 
validity was not reported. Construct validity was examined with convergent and 
discriminative validations. Moderate to strong correlations were found between the 
subscale scores of the HF Symptom Survey and the Kansas City Cardiomyopathy 
Questionnaire, which measures health-related quality of life in patients with HF (r = -
0.62 to -0.78).112 Symptom frequency and severity scores in the HF Symptom Survey 
increased significantly as New York Heart Association (NYHA) functional class 
increased from I to IV.112  
The HF Signs and Symptoms Checklist. Content validity was evaluated by a panel 
of four HF experts (three advanced practice nurses and one master’s prepared cardiac 
patient educator).107  Lynn’s method,116 which consists of a two-stage content validity 
process (instrument development and quantification of content validity using Index of 
Content Validity), was used to ascertain content validity.  
Criterion validity was not explored. Construct validity was supported by 
demonstrating the association between symptom scores (the number of symptoms 
reported by patients) and their functional status measured by NYHA functional class.107 
Patients in a hospital care setting experienced more symptoms than patients in an 
ambulatory care setting.107 
The HF Symptom Checklist. The items in the HF Symptom Checklist were 
identified from HF symptoms listed in the Agency for Health Care Policy Research 1994 
publication on HF practice guidelines.102, 105-106 Two cardiac clinical nursing specialists 
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validated the items.102, 105-106 High correlations were reported between the items in the HF 
Symptom Checklist and a symptom checklist which was developed for medical record 
reviews.102, 105-106 No information about construct validity was available. 
The M.D. Anderson Symptom Inventory-HF. Heart failure symptom items were 
generated by literature review, patient interviews, and HF experts and refined by a panel 
of HF experts (10 cardiologists and 10 advanced practice nurses with HF specialty).108 To 
ensure content validity the panel of HF experts was carefully selected based on three 
criteria (cardiology practice for at least five years, at least one publication related to HF 
management, and considered an expert by the HF community). Index of Content Validity 
was used to rate the relevance of items by the expert panel.108  Initially, 30 items were 
included in the MDASI-HF, and three items were removed (i.e., depression, anxiety, and 
limitation of physical activity) due to item redundancy identified via cluster analysis.108  
Criterion validity using concurrent validation was supported by moderate 
correlations of two commonly used symptom measures with the MDASI-HF (r= 0.59-
0.62 for NYHA functional class and r= 0.55-0.65 for the Eastern Cooperative Oncology 
Group, respectively).108 Construct validity was evaluated by comparing differences in 
average severity and interference scores by B-type natriuretic peptide (BNP) categories 
formed using the cutoff point of 100 pg/mL, which reflects volume expansion and 
pressure overload in the left ventricle. Significant group differences were observed in 
symptom severity scores but not interference scores.108 Factor analysis was performed 
using eight HF symptom items. Two underlying factors emerged: (1) overt HF symptoms 
(nighttime cough, paroxysmal nocturnal dyspnea, fatigue, orthopnea, and palpitations); 
and (2) covert HF symptoms (sudden weight gain, abdominal bloating, and edema).108  
The Memorial Symptom Assessment Scale-HF. Information on the validity of the 
MSAS-HF was limited. Zambroski and colleagues modified the MSAS by adding five 
HF-specific symptoms and eliminating five cancer-specific symptoms from the MSAS.  
No information was available about the content validation (content relevance and 
representativeness) of the modified items in HF patients. Information supporting criterion 
validity was not reported. The construct validity was supported by demonstrating that 
patients with HF had higher scores in symptoms prevalence than healthy adults without 
HF.113 Symptom burden and prevalence scores were significantly associated with scores 
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of the Minnesota Living with HF Questionnaire, which measures health-related quality of 
life.8  
Completion Process 
Completion time was not available except for the HF Symptom Checklist. It took 
approximately 10 minutes for patients to complete the 13-item HF Symptom Checklist.106 
All instruments were designed to be a paper-pencil format as opposed to a computerized 
format.  
Information 
There was limited information about changes in symptom scores in relation to 
symptom management. There was a small correlation (r=0.34) between scores of the HF 
Symptom Checklist administered during hospitalization with scores 4 to 6 weeks after the 
index hospitalization.102  Most studies using the instruments reviewed were cross-
sectional in nature, which limited the ability to examine how scores in symptom measures 
were responsive to treatment or changes.  
The associations between scores in the symptom measures and outcomes (e.g., 
quality of life) and important factors associated with outcomes (e.g., depressive 
symptoms) were investigated in three studies.8, 102, 108 In a study in which the MSAS-HF 
was used, the scores of total symptom prevalence and total symptom burden scores 
predicted health-related quality of life.8 In another study in which the HF Symptom 
Checklist was used, symptom scores at baseline (during hospitalization) explained 13% 
of the variance in scores of depressive symptoms 4-6 weeks after the index 
hospitalization.102  Symptom severity scores measured with the MDASI-HF were 
significantly different between patients who had high and low BNP levels.108   
Discussion 
We reviewed five symptom measures that have been designed for and used in the 
HF population.  The challenge in this review was the dearth of information about the 
development process and psychometric properties of symptom measures. There were 
only one article 108 and two proceedings112-113 aimed at exploring psychometric properties 
of symptom measures. None of the symptom measures reviewed in this paper provided 
sufficient information on all five criteria used to evaluate instrument quality.  
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The level of comprehensiveness of symptom measures varied among the five 
measures reviewed. The variability in content among symptom measures may be 
associated with instrument developers’ views of the separateness of symptoms.  In the HF 
Signs and Symptoms Checklist, “nausea, vomiting, diarrhea and/or loss of appetite,” 
which are gastrointestinal-related problems, were assessed with one item. In the MSAS-
HF feeling nervous and feeling irritable, which are the characteristics of anxiety,117 were 
counted as separate symptoms. A possible problem with combining symptoms together is 
that healthcare providers are not able to figure out exactly which symptoms are 
experienced by patients without further probing. On the other hand, too fine a separation 
of symptoms may be unwarranted as patients are often unable to distinguish subtle 
differences between similar symptoms.  
Another factor related to the content variability may be what kinds of symptoms 
(typical or atypical HF symptoms) instrument developers intended to measure. The HF 
Symptom Checklist consisted of typical HF physical symptoms, while the other four 
included typical as well as atypical HF symptoms. In an initial clinical assessment, 
instruments containing a variety of symptoms may be beneficial in order to gain a fuller 
picture of patients’ symptom experiences. Given that multiple comorbid conditions and 
polypharmacy are common in patients with HF, patients often experience cardiac and 
non-cardiac symptoms.33, 118 A comprehensive symptom instrument can serve as a 
prompt for patients to ensure that they provide information about all symptoms they are 
experiencing. After the initial assessment with a comprehensive symptom measure, 
healthcare providers may determine which symptom measures, either HF symptom-
focused or full version, can be used for the follow-up visits depending on patients’ 
symptom experiences.  
Including different symptom dimensions also influences the variability in the 
content. The MSAS-HF and the HF Symptom Survey contained three dimensions while 
the HF Signs and Symptoms Checklist and the HF Symptom Checklist had one 
dimension (presence or absence of symptoms).  A multi-dimensional approach to 
symptom assessment is important because simple presence or absence of symptoms does 
not fully describe symptom experiences.119 However, there are issues with the length of 
multi-dimensional symptom measures and their potential use in a busy clinical setting, 
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given that the completion time for the 13 item-HF Symptom Checklist was approximately 
10 minutes.106   
Information about reading levels was not available for the five measures reviewed 
in this paper. Albert and colleagues addressed their efforts in selecting simple, easy 
wordings to describe symptom items in the HF Signs and Symptoms Checklist.107 Also, 
the authors included operational definitions of symptom items. For example, sudden 
weight gain was defined as “a greater than 2 pounds in a day or 5 pounds in a week” in 
the HF Signs and Symptoms Checklist. Providing definitions helps patients understand 
the meaning of symptom items by increasing the clarity of items.107 It is also beneficial 
for healthcare providers to obtain accurate, reproducible results by conveying a consistent 
meaning of symptom items to patients.  However, it would be difficult to compare results 
among symptom instruments if each instrument developer defines similar symptoms 
differently. It is necessary to conduct critical evaluations of which definitions most 
properly describe symptoms. 
Although the optimal schedule for assessing symptom experience is unknown, a 
shorter timeframe is appropriate because symptom status changes quickly.32 The 
MDASI-HF can be used for daily symptom assessment, while the other four measures 
can be used for intermittent assessment.  
Clear instructions to patients are important in order to obtain quality data. 
Inadequate instructions led to the problem of patients providing frequency or severity 
despite endorsing the absence of the same symptom.104 Similar errors were also reported 
by Chang and colleagues31 when they used the MSAS in the cancer population. Because 
the MSAS-HF used instructions similar to the MSAS, it is expected that this same 
problem may occur when the MSAS-HF is administered to HF patients. 
Scoring for each of the symptom measures was relatively easy. There were 
subscales in the MDASI-HF and MSAS-HF (e.g., HF symptom and psychological 
symptom subscales), which may be convenient for healthcare providers to selectively 
administer depending on their needs. Symptom burden scores in the MSAS-HF were 
computed by averaging scores of the three symptom domains. This method assumed that 
patients were equally burdened by symptom severity, frequency, or distress.120  
 
38 
The psychometric properties of the five measures have not been extensively 
investigated or reported. Of the four measures in which internal consistency was 
examined, good internal consistency was supported in all measures except for the HF 
Symptom Checklist. Stability has not been investigated in any symptom measure 
reviewed, which may be related to relatively rapid changes in symptom status.  
Four measures102, 107-109 showed evidence of content validity. Rigorous content 
validation processes were described by instrument developers by conducting literature 
review, using the Index of Content Validity, or consulting with a panel of HF experts. 
However, there is no report available regarding content validity of the MSAS-HF.  
Criterion validity was not commonly performed, which may be related to the fact 
that there is not a gold standard to measure symptoms in the HF population. Construct 
validity was demonstrated by convergent and discriminative validations (e.g., symptom 
score comparison by NYHA functional class) and factor analysis. However, as the 
validation process is ongoing, more validation studies about these measures are needed. 
Despite the dearth of information about psychometric properties, the MDASI-HF has 
been rigorously examined and showed sound psychometric properties.  
Symptom measure scores should be helpful to make clinical decisions and 
facilitate symptom management. Only three studies8, 102, 108 were identified and 
demonstrated that symptom scores were associated with outcomes. The limited 
information regarding clinical implications may be related to the fact that the five 
symptom measures were recently introduced (2001 to 2010).    
Conclusion 
Heart failure is a clinical syndrome which manifests a variety of symptoms. 
Symptom assessment and management are imperative to monitor the progress of illness 
and the impact of symptoms on outcomes. Symptom assessment is challenging as 
standardized symptom measures are lacking for patients with HF. Because existing 
symptoms measures are at a relatively early stage, the information regarding the criteria 
that we modified and amplified to examine the quality of symptom measures is not 
sufficient. More studies are needed to further validate existing HF symptom measures 
before one can be recommended for research and clinical use. 
Copyright © Kyoung Suk Lee 2012 
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Table 3.1. Evaluation criteria of ideal symptom instruments categories 
Category Characteristics Evaluation criteria 
Contents Comprehensiveness • The number of symptoms included 
• Description of symptom items 
• Symptom dimensions assessed (i.e., 
prevalence, frequency, severity, and 
distress) 
• Symptom clusters (co-occurring 
symptoms) 
Measuring 
scales 
• Simplicity and ease of 
the instrument 
completion 
• Suitability in clinical 
and research purposes  
• Reading level  
• Timeframe of symptoms experience 
• Completion rates 
• Complexity of scoring system 
• Brevity 
Psychometric 
properties 
• Accuracy  
• Precision 
• Reliability (internal consistency and test-
retest reliability) 
• Validity (content, criterion, and construct 
validity) 
Completion 
process 
Burden of the instrument 
completion 
• Time to completion 
Information Clinical implications • Association with prognosis (e.g., 
survival and quality of life) and 
important factors related to prognosis 
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Table 3.2. Symptom measures reviewed 
Contents Measuring Scale 
Validity Completion 
process Information Reliability Validity 
Heart Failure Symptom Survey112-Modified version of cardiac symptom scale   
Number of symptoms:  
14 symptoms (12 physical and 2 
psychological symptoms) 
Domain: 
• Frequency 
• Severity 
• Interference with physical 
activity 
• Interference with 
enjoyment of life  
Symptom Cluster: not addressed 
Reading level: NA 
Number of items: 56 items 
Timeframe: during the past 7 
days  
Incompletion rates: < 3% per 
symptom 
Scoring system: 
• An 11-point numeric 
rating scale 
• Averaging scores of 
each symptom  
Internal 
consistency: 
Cronbach’s α of 
0.80-0.88 
Stability: NA 
Content validity: 
literature review 
and an expert 
panel  
Criterion 
validity: NA 
Construct 
validity: 
convergent and 
discriminative 
validity 
NA NA 
Table 3.2 (continued) 
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Contents Measuring Scale 
Validity Completion 
process Information Reliability Validity 
Heart Failure Signs and Symptoms Checklist107     
Number of symptoms:  
12 symptoms (12 physical 
symptoms) and 9 signs  
Domain: 
Presence or absence 
Symptom Cluster: not addressed 
 
 
  
Reading level: NA 
(considered wording of items 
in the process of the 
instrument development) 
Number of items: 29 items 
(24 to assess signs and 
symptoms, 4 to determine 
NYHA class, and 1 to assess 
additional symptoms/ signs 
that were not listed)  
Timeframe: during previous 
7 days 
Completion rates: NA 
Scoring system: the number 
of symptoms reported 
Internal 
consistency: NA 
Stability: NA 
 
 
Content validity: 
literature review 
and an expert 
panel 
Criterion 
validity: NA 
Construct 
validity: 
discriminative 
validity 
NA NA 
Table 3.2 (continued) 
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Contents Measuring Scale 
Validity Completion 
process Information Reliability Validity 
Heart Failure Symptom Checklist102     
Number of symptoms:  
13 symptoms (13 physical 
symptoms) 
Domain: 
Presence or absence 
Symptom Cluster: not addressed 
 
 
  
Reading level: NA 
Number of items: 13 items  
Timeframe: during previous 
2 weeks 
Completion rates: NA 
Scoring system: the number 
of symptoms reported 
 
Internal 
consistency: 
Cronbach’s α of 
0.68 
Stability: NA 
 
Content validity: 
literature review   
Criterion 
validity: 
concurrent 
validity 
Construct 
validity: NA 
Time to 
completion: 
10 minutes 
Small correlation 
(r=0.34) of the 
symptom scores 
before and after the 
treatment  
Symptom scores 
measured during 
hospitalization were 
explained 13% of the 
variance in 
depressive symptoms 
4-6 weeks after the 
index hospitalization 
Table 3.2 (continued) 
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Contents Measuring Scale 
Validity Completion 
process Information Reliability Validity 
†M.D. Anderson Symptom Inventory-Heart Failure108- Modified version of the M. D. Anderson Symptom Inventory 
Number of symptoms:  
21 symptoms (18 physical and 3 
psychological symptoms) 
Domain: 
• Severity 
• Overall symptom 
interference  
Symptom Cluster: not addressed 
 
Reading level: NA 
Number of items: 27 items 
(21 symptom severity items 
+ 6 overall symptom 
interference items) 
Timeframe: during last 24 
hours  
Completion rates: NA 
Scoring system: 
• An 11-point numeric 
rating scale 
• Averaging scores 
Subscales: HF symptoms, 
MDASI core symptoms, and 
symptom distress 
Internal 
consistency: 
Cronbach’s α of 
0.83-0.92 
Stability: NA 
 
Content validity: 
literature review, 
an expert panel, 
and patient 
interviews  
Criterion 
validity: 
concurrent 
validity 
Construct 
validity: 
discriminative 
validity and 
factor structure 
analysis 
NA NA 
Table 3.2 (continued) 
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Contents Measuring Scale 
Validity Completion 
process Information Reliability Validity 
Memorial Symptom Assessment Scale-Heart Failure113- Modified version of the Memorial Symptom Assessment Scale 
Number of symptoms:  
32 symptoms (27 physical and 5 
psychological symptoms) 
Domain: 
• Presence or absence 
• Frequency 
• Severity 
• Distress 
Symptom Cluster: not addressed  
Reading level: NA 
Number of items: 122 items 
(symptom frequency are not 
assessed in 6 symptoms) 
Timeframe: during the past 7 
days 
Completion rates: NA 
Scoring system: 
• 4- or 5-point rating scale 
• Averaging scores of each 
symptom  
• Composite score: burden 
scores (the mean of the 
frequency, severity, and 
distress of each 
symptom) 
Subscales: HF, physical, and 
psychological symptom 
subscales 
Internal 
consistency: 
Cronbach’s α of 
0.73-0.91 
Stability: NA 
 
 
Content validity: 
NA 
Criterion 
validity: NA 
Construct 
validity: 
convergent and 
discriminative 
validity 
 
NA Total symptom 
prevalence and total 
symptom burden 
predicted quality of 
life 
Note. NA=not available; HF=heart failure; NYHA=New York Heart Association  
† Targeting HF patients with cancer
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Table 3.3. Symptoms included in the symptom measures 
 HF Symptom Survey112 
HF Signs and 
Symptom 
Checklist107 
HF Symptom 
Checklist102 
M.D. Anderson 
Symptom 
Inventory-HF 108 
Memorial 
Symptom 
Assessment Scale-
HF 113
Shortness of breath  or trouble breathing  X X 
Shortness of breath with activity X  with exertion   
Shortness of breath at rest X     
Shortness of breath when lying 
flat X 
need to use more 
than 1 pillow to 
sleep on at night; 
sleeps in a 
reclining position, 
shortness of breath 
(trouble breathing) 
when lying flat 
X 
difficulty sleeping 
without adding 
pillows 
X 
Waking up breathless at night 
shortness of breath 
when you wake up   
during the night 
wake up from a 
sound sleep & 
unable to breathe 
without sitting up 
in bed 
X X X 
Difficulty sleeping X   X X 
Swelling feet, ankles, or legs or edemaa feet or ankles ankle arms or legs 
Weight gain  
sudden (> 2 lbs in 
a day or > 5 lbs in 
a week) 
X sudden X 
Weight loss  X   X 
Table 3.3 (continued) 
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 HF Symptom Survey112 
HF Signs and 
Symptom 
Checklist107 
HF Symptom 
Checklist102 
M.D. Anderson 
Symptom 
Inventory-HF 108 
Memorial 
Symptom 
Assessment Scale-
HF 113
Fatigue or tiredness b profound fatigue with exertion c X X  
Weakness  generalized c X   
Lack of energy Xb   X X 
Cough worsening 
severe (keeps you 
awake at night or 
chest hurts when 
coughing) 
dry and hacking nighttime X 
Poor appetite  loss of appetite d X X X 
Change in the way food tastes     X 
Dry mouth    X X 
Nausea  X d X X X 
Vomiting  X d  X X 
Feeling bloated 
full or bloated 
feeling in your 
abdomen 
right sided 
abdominal / belly 
fullness or 
discomfort & 
tenderness 
 X X 
Feeling drowsy    or sleepy X 
Dizziness or lightheadedness or lightheadedness X  X 
Palpitations  
or feels like heart 
is racing in chest or 
you can feel your 
heart beating fast 
X X X 
Table 3.3 (continued) 
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 HF Symptom Survey112 
HF Signs and 
Symptom 
Checklist107 
HF Symptom 
Checklist102 
M.D. Anderson 
Symptom 
Inventory-HF 108 
Memorial 
Symptom 
Assessment Scale-
HF 113
Irregular heartbeat or fluttering feeling in chest 
or feels like heart 
beat is skipping    
Chest pain pressure or heaviness in chest X X  X 
Pain    X X 
Sweats     X 
Constipation     X 
Diarrhea  Xd   X 
Problem with urination  
change in urine 
output compared to 
normal (darker 
color, voiding less 
often or in smaller 
amounts) 
  X 
Problems with sexual interest or 
activity     X 
Numbness/tingling in hands/feet    numbness X 
Itching     X 
Wheezing  X    
Worrying     X 
Feeling nervous     X 
Feeling sad depressed or feeling down   X X 
Table 3.3 (continued) 
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 HF Symptom Survey112 
HF Signs and 
Symptom 
Checklist107 
HF Symptom 
Checklist102 
M.D. Anderson 
Symptom 
Inventory-HF 108 
Memorial 
Symptom 
Assessment Scale-
HF 113
Feeling distress    X  
Feeling irritable     X 
Difficulty concentrating Xe    X 
Restlessness  or confusion    
Difficulty remembering forgetfulness e   X  
Decreased ability to exercise or 
carry out activities  X    
Low blood pressure or low blood 
pressure when sitting or standing  X    
Feel like you are going to faint or 
actually fainted (black out)  X    
Cool, pale, or mottled skin  X    
Heart rate < 60 beats per minute 
or > 120 beats per minute  X    
Note. HF=Heart failure 
a Patients are asked to check the box to indicate the swelling sites (ankles or legs; abdomen; or all over) 
b Fatigue, tiredness or lack of energy were assessed with one item 
c Profound fatigue with exertion or generalized weakness were assessed with one item 
d Nausea, vomiting, diarrhea and/or loss of appetite were assessed with one item. 
e Difficulty concentrating or forgetfulness was assessed with one ite
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CHAPTER FOUR 
Association of Physical versus Affective Depressive Symptoms with Cardiac Event-Free 
Survival in Patients with Heart Failure  
Introduction 
Heart failure (HF) is a growing health care concern associated with adverse 
outcomes and staggering health care expenditures.37 In addition to traditional risk factors 
(e.g., age and comorbidities),121-122 psychological status is recognized as a significant 
predictor of outcomes.63, 70-71, 122 Depressive symptoms are related to poor prognosis and 
quality of life in patients with HF.63, 70-71, 73, 122-123 Thus, it is important for health care 
providers to recognize and manage depressive symptoms appropriately in the HF 
population.  
Depressive symptoms are common in patients with HF, with a prevalence from 
30% to 51%.71, 73, 123-126 This large variability might be related to the selection of 
instruments to measure depressive symptoms and their cut points for defining varying 
levels of depressive symptoms.127 Instruments used to measure the levels of depressive 
symptoms often include physical depressive symptoms, such as changes in appetite, sleep 
disturbances, or fatigue. However, these symptoms are frequently reported by patients 
with HF.39, 124 This poses a challenge for health care providers to accurately screen and 
monitor depressive symptoms because these physical depressive symptoms may reflect 
the severity of HF rather than depressive symptom status.128  
Patients in more advanced stages of HF have greater physical symptom 
prevalence and burden than those in less advanced stage of HF.50 Patients with depressive 
symptoms experience more physical symptoms of HF (dyspnea, fatigue, sleep 
disturbance, and loss of appetite) than patients without depressive symptoms.124 Thus, the 
inclusion of physical symptoms might reflect HF severity, inflate the severity of 
depressive symptoms, and in turn, artificially increase their impact on outcomes in HF.  
Researchers have expressed concern about measuring depressive symptoms in 
patients with HF using instruments that include physical symptoms.34, 129 One way to 
address this concern is to use an established depressive symptom instrument such as the 
Patient Health Questionnaire (PHQ-9) that includes physical and affective depressive 
symptoms to compare the predictive ability between versions of the instrument with and 
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without physical depressive symptoms. The purpose of this study was to determine 
whether the presence of physical depressive symptoms on the PHQ-9 over-estimates the 
relationship of depressive symptoms to cardiac event-free survival. The specific aim was 
to compare the predictive ability for cardiac event-free survival of the full PHQ-9 with 
versions that contain just the physical and just the affective depressive symptoms after 
adjusting for health status and clinical and socio-demographic variables.   
Methods 
Design, Setting, and Procedure 
This study was a prospective, longitudinal investigation. Patients with HF were 
recruited from outpatient clinics associated with two academic medical centers in 
Georgia and Kentucky from August 2004 to March 2009. This study was approved by the 
Institutional Review Boards at each study site. Patients with HF were identified by 
referral from their nurses and physicians, and their eligibility was confirmed by trained 
research nurses. Signed, informed consent was obtained from patients who agreed to 
participate in the study during a visit to the General Clinical Research Center (GCRC). 
Patients were interviewed to collect demographic and clinical data and completed 
questionnaire packets during the visit to the GCRC. Patients were followed up over a 
median of 360 days (2 – 1826 days) to determine cardiac events. 
Participants 
Patients who met the following criteria were eligible for this study: (1) diagnosis 
of  HF by a cardiologist using the Framingham criteria 130; (2) no myocardial infarction 
within the previous three months; (3) taking consistent doses of HF medications at the 
time of study participation; and (4) able to read and speak English. Patients who had 
valvular heart disease as an etiology of their HF, were referred for heart transplantation, 
had obvious cognitive impairments, or had major life-threatening comorbidities (e.g., 
end-stage renal or liver disease or cancer other than skin cancer) were excluded.  
Measurement 
Depressive symptoms. Depressive symptoms were assessed using the PHQ-9, 
which consists of nine items (Table 1).131 Each item corresponds to one of the nine 
symptoms of the major depressive disorder criteria of the Diagnostic and Statistical 
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Manual of Mental Disorders-IV (DSM-IV). Patients rate items based on how often they 
experience these symptoms over two weeks on a 4-point Likert scale ranging from 0 (not 
at all) to 3 (nearly every day). The scores were summed and ranged from 0 to 27, with 
scores of  ≥ 5, ≥ 10, ≥ 15, and ≥ 20, representing mild, moderate, moderately severe, and 
severe levels of depression symptoms, respectively. The validity of the PHQ-9 has been 
demonstrated to screen for depression in patients with cardiac disease with high 
specificity and predictive value.132 Its brevity makes its use in clinical settings or research 
desirable.133  
Three items related to sleep disturbance, fatigue, and appetite change were 
classified as comprising the PHQ-9 physical depressive symptom dimension in this study 
because these are often experienced by patients with HF.38-39 The remaining six items of 
anhedonia, depressed mood, negative feelings about oneself, concentration problems, 
psychomotor agitation/ retardation, and suicidal ideation were classified as comprising 
the PHQ-9 affective depressive symptom dimension. The reliability of the scores for the 
two dimensions of depressive symptoms in this study was measured using Cronbach’s α: 
0.764 for physical depressive symptom and 0.814 for affective depressive symptom 
dimensions. 
Health status and Clinical, socio-demographic characteristics. Health status in 
this study was operationally defined as comorbidity burden measured with the Charlson 
Comorbidity Index and functional status measured with New York Heart Association 
(NYHA) functional classification. The Charlson Comorbidity Index was used to measure 
comorbidity burden which is weighted by taking into account comorbid illnesses (i.e., the 
number and seriousness).64 New York Heart Association functional classification was 
determined to assess limitations of physical activities resulting from symptoms by in-
depth structured interviews by a trained research nurse. Clinical and socio-demographic 
characteristics (e.g., medication and marital status) were collected via patient interviews 
and medical record reviews.  
Cardiac events. Cardiac events were defined as the composite end point of 
cardiac-related death, cardiac-related hospitalization, or emergency department (ED) visit 
attributable to cardiac reasons (e.g., worsening HF symptoms). The data were obtained by 
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monthly follow-up calls to patients and their families and confirmed by reviewing 
medical records and public death records.  
Statistical Analyses 
Data were analyzed using SAS software version 9.2 (SAS Institute Inc, Cary, 
North Carolina). Unadjusted Cox proportional hazards regressions were performed 
separately for physical and affective depressive symptom dimensions of the PHQ-9 in 
order to examine predictive ability for time to first cardiac event. Two series of 
multivariable analyses were done. Health status (the Charlson Comorbidity Index and 
NYHA class) was entered as covariates in the first model and health status and clinical, 
socio-demographic variables (age, gender, etiology of HF, body mass index [BMI], and 
anti-depressant medication therapy) were entered together in the second model. 
Covariates included in the models were selected a priori based on previous studies.34, 73, 
121, 129, 134  
The seven covariates included in our survival analysis models resulted in a ratio 
of seven events per predictors, which is lower than the recommended 10 events per 
predictor for survival analysis. To determine whether models with seven covariates 
provided reliable prediction, we ran progressive models in which the least significant 
predictors were removed one by one and compared information criteria values (e.g., 
Akaike's information criterion) among the models. The information criteria values in the 
reduced models were similar to the full model with seven covariates. Therefore, given 
that all covariates were identified as important in prior research we included all seven 
covariates in the analyses. 
The proportional hazards assumptions were evaluated with graphical displays of 
deviations between the observed cumulative martingale residuals and the values of each 
explanatory variable from 20 random simulations. The Kolmogorov-type supremum tests 
from 1000 simulated patterns also were used. Both methods indicated that there was not a 
gross violation of the model assumption.     
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Results 
Sample Characteristics 
A total of 210 patients with HF participated in the study (Table 2). The majority 
of patients were male, Caucasian, and married or cohabitating. Ischemia was the most 
common HF etiology. The median score of the PHQ-9 was 4 (the first and third quartiles: 
1 and 9, respectively). Patients having moderate to severe depressive symptoms (PHQ-9 
scores ≥ 10) were 23% (49/210) of total participants.  Of these patients having moderate 
to severe depressive symptoms, 41% (20/49) were prescribed anti-depressants.  
Patients were grouped by the median split of PHQ-9 scores for physical 
depressive symptom and affective depressive symptom dimensions (Table 2). The high 
PHQ-9 physical depressive symptom group (scores > 3) had a greater proportion in 
NYHA functional classes III and IV, higher comorbidity burden scores, and a greater 
number of prescribed anti-depressants than the low PHQ-9 physical depressive symptom 
group (scores ≤ 3). The high PHQ-9 affective depressive symptom group (scores >1) 
were younger and had a greater proportion in NYHA functional classes III and IV, higher 
comorbidity burden scores, and a greater number of prescribed anti-depressants 
compared to the low PHQ-9 affective depressive symptom group (scores ≤ 1). 
Cardiac Events 
During the follow-up period, 59 cardiac events occurred: 2% (4/210) were cardiac 
death, 23% (48/210) were cardiac-related hospitalizations, and 3% (7/210) were ED visits 
due to cardiac causes.  
Prediction of Cardiac Event-free Survival 
Full version of the PHQ-9. The total scores of the PHQ-9 predicted cardiac event-
free survival in the unadjusted and adjusted analyses (Table 3). The association between 
total scores of the PHQ-9 and time to first cardiac event remained significant after 
adjusting for the covariates (unadjusted hazard ratio [HR] = 1.08, 95% confidence 
interval [CI] =1.03 – 1.13; adjusted HR for health status [the Charlson Comorbidity Index 
and NYHA functional class] = 1.07, 95% CI =1.03 – 1.13).  Every one point increase in 
total PHQ-9 score was associated with a 6% increase in the risk for a cardiac event after 
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controlling for all covariates (adjusted HR for all covariates = 1.06, 95% CI =1.01 – 
1.12).   
PHQ-9 physical depressive symptom dimension. In the unadjusted Cox regression 
analysis scores of the PHQ-9 physical depressive symptom dimension were a predictor 
for cardiac event (unadjusted HR = 1.11, 95% CI =1.02 – 1.21). Scores of the PHQ-9 
physical depressive symptom dimension did not predict cardiac event-free survival after 
adjusting for health status. Neither the Charlson Comorbidity Index nor NYHA 
functional class predicted cardiac event-free survival.  
After entering all covariates, the association between scores of the PHQ-9 
physical depressive symptom dimension and cardiac event-free survival was not 
significant (Table 4). Only anti-depressant medication therapy was an independent 
predictor of cardiac event-free survival (adjusted HR = 1.98, 95% CI =1.06 – 3.71). 
Patients prescribed anti-depressants had nearly double the risk for a cardiac event than 
patients not prescribed anti-depressants. 
PHQ-9 affective depressive symptom dimension. The scores of the PHQ-9 
affective depressive symptom dimension predicted cardiac event-free survival in both 
unadjusted and adjusted models (unadjusted HR = 1.14, 95% CI =1.06 – 1.22). In the two 
series of multivariable analyses the association between scores of the PHQ-9 affective 
depressive symptom dimension and cardiac event-free survival remained significant. In 
the first model adjusting for health status, scores of the PHQ-9 affective depressive 
symptom dimension was the only predictor of cardiac event-free survival (adjusted HR 
for health status = 1.13, 95% CI = 1.05 – 1.21). In the second model adjusting for all 
covariates, scores of the PHQ-9 affective depressive symptom dimension independently 
predicted cardiac event-free survival (Table 5).  Every one point increase in the scores of 
the PHQ-9 affective depressive symptom dimension was associated with a 12% increase 
in the risk for a cardiac event (adjusted HR for all covariates = 1.12, 95% CI = 1.03 – 
1.22).  
Discussion 
We found different predictive outcomes for the PHQ-9 physical and affective 
depressive symptom dimensions in patients with HF. Both affective and physical 
depressive symptom dimensions were predictive of a cardiac event in unadjusted models. 
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However, affective depressive symptoms, but not physical depressive symptoms, 
persistently predicted time to cardiac event in adjusted models controlling for health 
status (the Charlson Comorbidity Index and NYHA functional class) and clinical, socio-
demographic factors. These results suggest that physical depressive symptoms may 
largely reflect health status, and the relationship between depressive symptoms and risk 
for a cardiac event is limited to affective depressive symptoms.  
There is evidence that affective depressive symptoms may be a useful indicator to 
detect levels of depressive symptoms. In the study of Holzapfel and colleagues affective 
depressive symptoms (e.g., depressed mood and worthless/ guilty) were more often 
reported by depressed patients with HF than those without HF, while the frequency of 
physical depressive symptom experience did not differ 128. In a study in which depressive 
symptoms were measured with the Beck Depression Inventory (BDI)-II, somatic 
depressive symptom scores were not different between patients with post acute 
myocardial infarction and psychiatric outpatients matched on age, gender, and 
cognitive/affective depressive symptom scores.135 Simon and Von Korff demonstrated 
that the overall pattern of physical symptoms, such as weight and appetite changes, 
fatigue, and sleep disturbances, was similar to depressed patients with and without 
chronic illness.136 The removal of overlapping physical symptoms from self-report 
depressive symptom instruments does not improve the discriminating ability for the 
presence of depression using diagnostic interview based on the DSM-IV criteria for 
major depressive episode in patients with chronic pain.137-138  
In the study of Azevedo and colleagues in which the association between 
depressive symptoms, which were measured with the BDI, and HF stages, which were 
defined by the American College of Cardiology and American Heart Association, 
patients with a higher stage (more advanced HF) had higher levels of depressive 
symptoms. This relationship between HF stages and depressive symptom levels remained 
significant after deleting physical symptom items (i.e., fatigue, sleep disturbance, and 
changes in appetite) from the BDI.34  
We found that the unique contribution of the physical depressive symptoms to 
risks for a cardiac event disappeared with the inclusion of health status (comorbidities 
and NYHA functional class) in regression models. This might indicate the significant 
 
 
56 
 
association between health status and physical depressive symptoms. There are several 
studies in which the relationship between health status and physical depressive symptoms 
was demonstrated. In a previous study in which the BDI was used to measure depressive 
symptoms in patients with HF scores of the BDI somatic/affective depressive symptom 
dimension (e.g., irritability, crying, fatigue, and sleep disturbances), but not scores of the 
BDI cognitive/ affective symptom dimension (e.g., sense of failure, self-accusation, and 
suicidal ideas), were different by NYHA classes.139 Significant differences in depressive 
symptom levels between patients with and without HF were observed only when using a 
depressive symptom measure incorporating physical symptoms (the Centers for the 
Epidemiological Studies of Depression Questionnaire), but not measures free of physical 
symptoms (Profile of Mood States-Short form dejection-depression and the Hospital 
Anxiety and Depression Scale-depression).140   
Similarly, the BDI somatic/affective symptoms, but not the BDI 
cognitive/affective symptoms, were significantly related to the Charlson Comorbidity 
Index in patients with myocardial infarction.141 Watkins and colleagues also showed a 
stronger relationship of comorbidities, which were measured by the Charlson 
Comorbidity Index, with the BDI physical depressive symptoms (r=0.24) than the BDI 
cognitive symptoms (r=0.06) in patients after acute myocardial infarction.142 
Barefoot and colleagues demonstrated the important role of affective depressive 
symptoms in predicting cardiac death among patients with coronary artery disease.143 
Hazard ratios of four depressive symptom dimensions, which were measured with the 
Zung Self-rating Depression Scale (SDS), were compared between unadjusted models 
and an adjusted model in which all depressive symptom dimensions were entered 
simultaneously. The hazard ratio of the SDS affective symptoms (e.g., sadness, 
irritability, restlessness, and suicidal ideas) remained similarly while the hazard ratios of 
the others including somatic (e.g., tiredness and sleep difficulties) and well-being (e.g., 
satisfaction and optimism) dimensions substantially reduced. Similarly, affective 
depressive symptoms were associated with cardiac mortality in patients after coronary 
artery bypass surgery while physical depressive symptoms were not.144 This result 
suggests that the relationship between depressive symptom levels and cardiac mortality is 
not altered by physical symptoms due to disease conditions.144   
 
 
57 
 
Conflicting findings that physical depressive symptoms, not affective depressive 
symptoms, predict cardiac outcomes (e.g., mortality or hospitalizations) are observed in 
previous studies in patients with coronary heart diseases, such as acute myocardial 
infarction.145-147 The significant relationship between physical depressive symptoms and 
all-cause mortality was also reported in the HF population.139 Schiffer and colleagues 
reported that the BDI somatic/affective symptom dimension (e.g., irritability, crying, 
fatigue, and sleep disturbances) was an independent predictor of all-cause mortality while 
the BDI cognitive/affective symptom dimension (e.g., sense of failure, self-accusation, 
and suicidal ideas) was not in patients with HF.139 This conflicting finding with the 
current study may be related to different outcome variables. The outcome of their study 
was all-cause mortality while ours was the combined end point of mortality, 
hospitalization, and ED visit related to cardiac reasons. The majority of cardiac events in 
this study were hospitalizations. It is possible that factors related to death are different 
from factors related to hospitalizations. For instance, left ventricular ejection fraction or 
NYHA functional class was an independent predictor of mortality, but not 
hospitalization.148-149  
The use of different measures to assess depressive symptoms may contribute to 
the inconsistent findings. The items in the BDI and the PHQ-9 are different although 
there are some items that are overlapped between the two measures including anhedonia, 
suicidal ideation, psychomotor agitation/ retardation, and fatigue. Physical and affective 
depressive symptom dimensions were defined with different items between the study of 
Schiffer et al. and ours. An item indicating psychomotor agitation/ retardation was 
categorized as the BDI somatic/affective symptom dimension in the study of Schiffer et 
al. while the item was categorized as the PHQ-9 affective depressive symptoms in our 
study.  
One interesting finding in this study is the association between being prescribed 
anti-depressants and higher risk for cardiac events. The prescription of anti-depressants 
was a significant predictor of a cardiac event in the multivariable model which included 
the PHQ-9 physical symptom dimension. However, this relationship was not significant 
in the adjusted models using total PHQ-9 scores or PHQ-9 affective symptom dimension 
scores. We extrapolate that the impact of taking anti-depressants differs by dimensions of 
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depressive symptoms. However, we cannot determine from out data whether patients 
prescribed anti-depressants actually took the medication or that the dose prescribed was 
adequate to treat depressive symptoms.  Therefore, our results should be interpreted as 
demonstrating that prescribing anti-depressants was associated with an increased risk for 
a cardiac event. Our results do, however, suggest that simply prescribing anti-depressants 
is not sufficient and without proper follow-up to assure adequate treatment, it may 
increase the risk for a cardiac event.   
It is important to acknowledge the differential influence of physical and affective 
depressive symptoms on cardiac event-free survival in patients with HF. The use of the 
measures including physical depressive symptoms does not inflate the association 
between depressive symptoms and cardiac event-free survival.  
There are limitations that should be noted in this study. The sample may not be 
representative of the HF population because men and Caucasians predominated. Because 
this was an observation study, no definitive inferences can be drawn regarding causal 
relationships. The number of covariates include in our multivariable models exceeded the 
recommended number of covariates per event. However, our model testing demonstrated 
that the full model provided as reliable prediction as models with fewer covariates 
without causing an overfitting issue. Therefore, the full model, which had empirical 
support, was the optimal model to include in the analyses.  
Conclusion 
The accurate assessment of depressive symptoms in patients with HF has been a 
critical issue because of their adverse effects on outcomes. However, shared physical 
symptoms between HF and depressive symptoms are barriers to prevent evaluating the 
severity of depressive symptoms in HF. In this study we demonstrated a distinctive 
prognostic ability between physical and affective depressive symptoms to outcomes in 
patients with HF. Affective depressive symptoms were associated with cardiac event-free 
survival independent of health status, but not physical depressive symptoms. The use of 
depressive symptom measures including physical symptoms does not inflate the 
relationship of depressive symptoms to cardiac event-free survival. Thus, clinicians can 
use instruments that contain physical depressive symptoms to assess depressive 
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symptoms in their patients with HF without concern that the instruments over-estimate 
the relationship between depressive symptoms and outcomes. 
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Table 4.1. Items of the Patient Health Questionnaire-9  
Items of the PHQ-9 physical depressive symptom dimension 
1.  Trouble falling/staying asleep, sleeping too much 
2.  Feeling tired or having little energy 
3.  Poor appetite or overeating 
Items of the PHQ-9 affective depressive symptom dimension 
1.  Little interest or pleasure in doing things 
2.  Feeling down, depressed, or hopeless 
3.  Feeling bad about yourself – or that you are a failure or have let yourself or your 
family down 
4.  Trouble concentrating on things, such as reading the newspaper or watching 
television 
5. Moving or speaking so slowly that other people could have noticed. Or the 
opposite – being so fidgety or restless that you have been moving around a lot 
more than usual 
6.  Thoughts that you would be better off dead or of hurting yourself in some way 
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Table 4.2. Sample characteristics (N=210) 
 Total PHQ-9 physical symptom dimension 
PHQ-9 affective 
symptom dimension 
  
Low scores 
(n=115) 
High scores 
(n=95) 
Low 
scores 
(n=126) 
High scores 
(n=84) 
 Mean (S.D) or N (%) 
Age, years b  61 (11) 63(12) 60 (10) 64 (11) 58 (11) 
Female  55 (26.2%) 26 (22.6%) 29 (30.5%) 29 (23.0%) 26 (31.0%) 
Ethnicity      
Caucasian  169 (80.5%) 91 (79.1%) 78 (82.1%) 
100 
(79.4%) 69 (82.1%) 
Others 41 (19.5%) 24 (20.9%) 17 (17.9%) 26 (20.6%) 15 (17.9%) 
Marital Status      
Married/ cohabitate 117 (55.7%) 65 (56.5%) 52 (54.7%) 72 (57.1%) 45 (53.6%) 
Single/ divorced/ 
widowed 93 (44.3%) 50 (43.5%) 43 (45.3%) 54 (42.9%) 39 (46.4%) 
Body mass index 
(kg/m2) 
31.6 (7.4) 31.1 (7.8) 32.2 (7.0) 31.4 (7.8) 31.9 (6.8) 
Charlson Comorbidity 
Index a, b 
3.4 (2.1) 3.1 (2.0) 3.7 (2.1) 3.2 (2.0) 3.6 (2.3) 
Ischemic etiology of 
HF 
158 (75.2%) 83 (72.2%) 75 (79.0%) 94 (74.6%) 64 (76.2%) 
NYHA class a, b      
I/ II 105 (50.0%) 70 (60.9%) 35 (36.8%) 74 (58.7%) 31 (36.9%) 
III/ IV 105 (50.0%) 45 (39.1%) 60 (63.2%) 52 (41.3%) 53 (63.1%) 
Medications      
Anti-depressant a, b 43 (20.5%) 12 (10.4%) 31 (32.6%) 15 (11.9%) 28 (33.3%) 
ACE I or ARB 
(n=209) 
172 (81.9%) 97 (85.1%) 75 (79.0%) 107 (84.9%) 65 (78.3%) 
Beta blocker 
(n=209) 
184 (87.6%) 104 (91.2%) 80 (84.2%) 
110 
(88.0%) 74 (88.1%) 
a Significant differences between groups with low and high scores of the PHQ-9 physical 
symptom dimension (median split), p-value < .05 
b Significant differences between groups with low and high scores of the PHQ-9 affective 
symptom dimension (median split), p-value < .05 
Note. HF: Heart failure; NYHA: New York Heart Association functional class; PHQ-9: the 
Patient Health Questionnaire-9; ACE I: Angiotensin-converting enzyme inhibitors; ARB: 
Angiotensin receptor blocking agents  
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Table 4.3. Multivariable Cox regression analysis using the total scores of the PHQ-9 
(N=210) 
 Hazard Ratio p-value 95% Confidence Interval 
Age 0.99 .41 0.97-1.01 
Female 0.85 .61 0.46-1.59 
Charlson Comorbidity Index 1.05 .53 0.91-1.20 
Ischemic etiology  2.14 .07 0.95-4.82 
NYHA Class (I/II vs. III/IV) 0.91 .76 0.51-1.64 
Body mass index (kg/m2) 0.96 .07 0.92-1.00 
Anti-depressant use 1.80 .07 0.96-3.36 
Total scores of the PHQ-9 1.06 .019 1.01-1.12 
Total model p-value =.001 
Note. NYHA: New York Heart Association functional class; PHQ-9: the Patient Health 
Questionnaire-9 
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Table 4.4. Multivariable Cox regression analysis using scores of PHQ-9 physical 
depressive symptoms (N=210) 
 Hazard Ratio p-value 95% Confidence Interval 
Age 0.99 .21 0.96-1.01 
Female 0.80 .48 0.42-1.50 
Charlson Comorbidity Index 1.06 .49 0.93-1.22 
Ischemic etiology  2.09 .08 0.93-4.71 
NYHA Class (I/II vs. III/IV) 0.96 .88 0.53-1.72 
Body mass index (kg/m2) 0.96 .06 0.92-1.00 
Anti-depressant use 1.98 .033 1.06-3.71 
PHQ-9 physical scores 1.07 .18 0.97-1.19 
Total model p-value =.007 
Note. NYHA: New York Heart Association functional class; PHQ-9: the Patient Health 
Questionnaire-9 
 
 
 
 
64 
 
Table 4.5. Multivariable Cox regression analysis using scores of PHQ-9 affective 
depressive symptoms (N=210) 
 Hazard Ratio p-value 95% Confidence Interval 
Age 0.99 .62 0.97-1.02 
Female 0.94 .83 0.50-1.75 
Charlson Comorbidity Index 1.04 .57 0.91-1.20 
Ischemic etiology  2.22 .06 0.98-5.02 
NYHA Class (I/II vs. III/IV) 0.94 .82 0.52-1.67 
Body mass index (kg/m2) 0.96 .08 0.92-1.00 
Anti-depressant use 1.83 .06 0.99-3.38 
PHQ-9 affective scores 1.12 .006 1.03-1.22 
Total model p-value <.001 
Note. NYHA: New York Heart Association functional class; PHQ-9: the Patient Health 
Questionnaire-9 
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CHAPTER FIVE 
The Association between Regular Symptom Monitoring and Self-Care Management in 
Patients with Heart Failure 
Introduction 
Heart failure (HF) is a serious health concern in the United States, with high 
mortality and rehospitalization rates. Approximately half of the patients who are 
diagnosed with HF will die within five years.2 Although HF rehospitalization rates have 
decreased over 10 years from 1998 to 2008,150 HF remains the most common reason for 
rehospitalizations among Medicare beneficiaries.151 A majority of rehospitalizations due 
to worsening HF are preventable with active engagement in self-care, such as following a 
low sodium diet.152-153 According to Annema and colleagues, up to 18% of HF 
rehospitalizations can be attributed to a delay in seeking help for escalating symptoms.152 
If patients monitor their symptoms on a regular basis and are aware of early symptoms 
and signs of HF exacerbation, HF readmission may be avoidable.  
Self-care is conceptualized as a naturalistic decision making process by patients to 
maintain physiological stability (self-care maintenance) and respond to changes in their 
symptom status (self-care management).29 Self-care maintenance consists of two 
components, monitoring symptoms and adhering to treatment regimens. Self-care 
management includes the following processes: recognizing altered symptom status, 
evaluating the changes in symptoms, deciding what actions to take, performing treatment 
strategies, and evaluating the results of actions taken.29 It is suggested that patients who 
monitor symptoms are able to detect and interpret escalating symptoms in a timely 
manner and initiate successful self-care management.29 However, the empirical evidence 
demonstrating the relationship between adherence to symptom monitoring behaviors and 
engagement in self-care management is lacking.  
The purpose of this study was to examine the relationship of adherence to regular 
symptom monitoring, which is defined as always checking weights and lower extremity 
edema, with adequate self-care management among HF patients who experienced 
dyspnea or edema in the past month. We hypothesized that adequate self-care 
management would be predicted by adherence to regular symptom monitoring behaviors. 
The first specific aim was to compare differences in self-care management behaviors 
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among three groups of patients based on adherence to two types of symptom monitoring 
behaviors (i.e., monitoring weights and lower extremity edema): patients who were 
adherent to (1) both symptom monitoring behaviors; (2) either of the symptom 
monitoring behaviors; and (3) neither of the symptom monitoring behaviors.  The second 
specific aim was to examine whether membership in one of the three symptom 
monitoring adherence groups predicted adequacy of self-care management.  
Methods 
The investigation was a cross-sectional, observational examination of the 
association between adherence to regular symptom monitoring and adequate self-
management in patients with HF. Patients were enrolled from HF clinics from six large 
community hospitals and academic medical centers in Kentucky, Georgia, and Indiana. 
Institutional Review Board approval was obtained at all sites. All patients who agreed to 
participate in the study provided signed, informed consent and visited the General 
Clinical Research Center to complete questionnaire packets and interviews. 
Patients 
Prospectively patients were identified by physicians and nurse practitioners. 
Research nurses approached eligible patients, explained the study in detail, and obtained 
informed consent if the patients agreed to participate in the study. Patients who met the 
following criteria were eligible for the study: (1) confirmed diagnosis of HF; (2) dyspnea 
and/or edema over the past one month; (3) stable dosage of medications for at least three 
months; (4) no myocardial infarction within the three months prior to starting the study; 
(5) no referral for heart transplant; (6) free of noncardiac serious or life-threatening 
comorbid conditions (e.g., end-stage renal or liver disease); (7) free of obvious cognitive 
impairment that prevented providing informed consent and completing the questionnaire 
packets; and (8) English-speaking.  
Measurements 
Symptom Monitoring Behaviors. In this study, symptom monitoring behaviors 
were defined as monitoring weight and lower extremity edema, and assessed with two 
items from the self-care maintenance subscale of the Self-Care of Heart Failure Index 
(SCHFI).154 Patients were asked how frequently they weighed themselves and checked 
 
 
67 
 
lower extremity swelling in the last month and could rate these items on a scale of 1 
(never or rarely) to 4 (always). Patients were considered adherent to symptom monitoring 
if they reported monitoring always. The following three patient groups were created 
based on levels of adherence to the two items (weight and lower extremity edema 
monitoring): adherent to (1) both items (i.e., adherent group); (2) either of the items (i.e., 
partially adherent group); and (3) neither of the items (i.e., non-adherent group). 
Self-Care Management. Self-care management was measured with the self-care 
management subscale of the SCHFI.  The self-care management subscale is comprised of 
six items capturing symptom recognition (i.e., shortness of breath or edema), 
implementation of treatment strategies (i.e., taking an extra diuretic dose, restricting fluid 
and sodium intake, and seeking advice from healthcare providers), and treatment strategy 
evaluation. Patients could rate items related to the implementation of treatment strategies 
on a 4-point Likert scale and items related to symptom recognition and treatment strategy 
evaluation on a 5-point Likert scale. The scores were standardized to range from 0 to 100, 
with higher scores indicating better self-care management. A score of 70 or greater 
(based on prior evidence) was considered adequate self-care management.154 Its 
reliability and validity have been supported in previous studies.154  
Functional Capacity.Functional capacity was measured with the Duke Activity 
Status Index (DASI), which is a 12-item self-administered questionnaire.155 The items in 
the DASI represent daily activities (e.g., personal care, ambulation, and household tasks). 
Each item is weighted by the estimated metabolic equivalents of task (MET) level 
associated with the activity in the item. Total scores can range from 0 to 58.2, with higher 
scores indicating fewer physical limitations and greater functional capacity.  
Sociodemographic and Clinical data. Data on age, gender, ethnicity, marital 
status, and medication regimens were collected via patient interview and medical records 
review. The interview format of the Charlson Comorbidity Index was used to obtain total 
comorbidity scores by taking into account the number and seriousness of comorbid 
conditions.156 Data on left ventricular ejection fraction (LVEF) and HF etiology were 
collected from the medical records. Patients were categorized as having either non-
preserved systolic function (LVEF ≤ 40%) or preserved systolic function (LVEF > 40%) 
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with a cutoff of 40%. New York Heart Association (NYHA) functional classification was 
determined by trained research nurses via in-depth structured patient interviews. 
Statistical Analyses 
Data were analyzed by SAS (version 9.3). Descriptive statistics including 
frequency distributions, means, and standard deviations were used to describe 
sociodemographic and clinical characteristics. Chi-square tests or Fisher’s exact tests of 
independence for categorical variables and one-way analysis of variance (ANOVA) for 
continuous variables were used to compare the differences in sociodemographic and 
clinical characteristics among three symptom monitoring adherence groups (i.e., 
adherent, partially adherent, and non-adherent groups). Bonferroni post-hoc test was 
performed if F-tests for ANOVA were significant (p-value < 0.05).   
Univariable and multivariable logistic regression analyses were conducted to 
explore the association between the levels of symptom monitoring adherence and the 
adequacy of self-care management. An outcome variable (self-care management) was 
dichotomized for binary variables with the cutpoint of 70.154 The confounding factors that 
were included in the multivariable model were age, gender, marital status, ethnicity, the 
Charlson Comorbidity Index, NYHA functional class, etiology of HF, LVEF, functional 
capacity measured with the DASI, and diuretic medication therapy. Receiver Operating 
Characteristic curves were used to assess model fit. 
Results 
Sample Characteristics 
The sample (N= 311) was predominantly male, white, and married or cohabitating 
(Table 1). More than half of the sample were in NYHA functional class III/IV and had 
non-preserved systolic function with LVEF ≤ 40%. Average levels of self-care 
management were generally low with the mean score of below 70, which is the cutpoint 
for the adequacy of self-care management.154 Less than half the total sample reported that 
they always monitored their weights (72/311) and lower extremity edema (112/311) 
(Figure 1). As described previously, three adherence groups were formed based on 
adherence to two symptom monitoring behaviors. A total of 15.1% (47/311) of patients 
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were in the adherent group, 28.9% (90/311) in the partially adherent group, and 56.0% 
(174/311) in the non-adherent group.   
The demographic and clinical variables that differentiated among the three groups 
were ethnicity and etiology of HF. Patients in the adherent group were more likely to be 
White and have ischemic heart disease as the underlying etiology of HF than patients in 
the partially adherent and non-adherent groups. Diuretics were prescribed more often in 
patients in the adherent group than patients in the other two groups. Self-care 
management scores were significantly different among groups. The percentage of 
patients who performed adequate self-care management (self-care management scores of 
≥ 70) were 38.3% (18/47) in the adherent, 25.6% (23/90) in the partially adherent, and 
13.2% (23/174) in the non-adherent group. 
Comparison of Self-care Management among Symptom Monitoring Adherence 
Groups 
Of the total sample, 13% of patients failed to identify changes in symptoms 
(Table 2). None of the patients in the adherent group failed to recognize their symptoms, 
while approximately one out of five patients in the non-adherent group did not recognize 
symptom changes.  
Among four possible treatment strategies to ameliorate worsening symptoms, 
reduced sodium intake was most likely to be performed while taking an extra diuretic was 
the least likely to be done by all patients. There were significant group differences with 
regard to limitation of sodium and fluid intake, and taking extra diuretics; however, there 
was no group difference in obtaining medical advice from healthcare providers (Table 2). 
When dyspnea or lower extremity edema was experienced, one of five patients 
did not do anything. Only half of the patients who took actions to relieve worsening 
symptoms were sure or very sure of the effectiveness of their actions. Compared to 
patients in the partially adherent or non-adherent groups, more patients in the adherent 
group responded to altered symptom status and reported that they were sure or very sure 
of the effectiveness of their actions.  
 
 
70 
 
Association between Symptom Monitoring Adherence Groups and Adequate Self-
care Management 
Adequacy of self-care management was significantly associated with membership 
in one of the three symptom monitoring adherence groups. In a univariate model, 
compared to patients in the non-adherent group, the odds of performing adequate self-
care management were two times and four times higher in patients in the partially 
adherent (odds ratio [OR] 2.27; 95% confidence interval [CI] 1.19 - 4.33) and adherent 
groups (OR 4.10; 95% CI 1.97 – 8.54), respectively.  
A full multivariable logistic regression model was presented in Table 3. Symptom 
monitoring adherence group, diuretic therapy, and NYHA functional class were 
significant independent predictors of adequate self-care management. The adjusted odds 
of performing adequate self-care management were increased by 240% (95% CI 1.19-
4.81) and 347% (95% CI 1.55-7.74) for the partially adherent and adherent groups, 
respectively. Patients who were prescribed diuretics were at six times higher odds of 
engaging in adequate self-care management than patients who were not, after adjusting 
for other variables in the model (95% CI 1.76 - 20.64).  Patients in NYHA functional 
class III/IV had a 2.2-fold increase (95% CI 1.09 - 4.57) in their odds of performing 
adequate self-care management after controlling for other variables.  
Discussion 
Results of this study contribute to the body of literature suggesting the importance 
of regular symptom monitoring to adequate self-care management. Adequacy of self-care 
management was predicted by adherence to symptom monitoring behaviors measured by 
always monitoring weight and lower extremity edema. Patients who engaged in both 
symptom monitoring behaviors were more likely to identify altered symptom status, 
implement treatment strategies to relieve worsening HF status, and evaluate the 
effectiveness of their responses.   
Monitoring signs and symptoms for congestion is important because one of the 
most common reasons for hospitalizations in patients with HF is volume overload. 
Because weight gain does not always reflect HF deterioration,30 it is important to 
simultaneously monitor a range of signs and symptoms of volume overload, including 
weight gain and lower extremity edema. However, of 311 patients in this study only 15% 
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reported that they performed daily weight and lower extremity edema monitoring. More 
than half of the patients did not monitor their symptoms on a daily basis even though they 
experienced dyspnea or lower extremity edema during the past month.  
Poor adherence to symptom monitoring has been demonstrated in previous 
studies. More than half of patients with HF do not weigh themselves daily.157-163 Only 9% 
of patients who were recently discharged from the hospital due to decompensated HF 
reported monitoring for symptoms of worsening HF.160  
Reasons for not monitoring signs and symptoms of congestions may be related to 
a lack of knowledge and motivation. Less than 40% of patients with HF were unaware 
that swelling of the legs and ankles, waking up at night due to shortness of breath, and 
weight gain were signs and symptoms of worsening HF.164  Patients simply do not know 
that they should monitor their weight or are not informed of the importance of daily 
weight monitoring by their healthcare providers.157, 159 Patients decide not to weigh 
themselves because they do not know how to use the information, even if they are aware 
of the importance of this behavior.159, 165 Gallagher suggests that poor adherence to 
symptom monitoring is related to patients’ misconception about HF, which is perceived 
as an acute illness. 166 As patients believe HF is present when symptoms are present, they 
may not value daily symptom monitoring when they do not experience symptoms 
limiting their daily activities. 
The notion that adhering to symptom monitoring facilitates self-care management 
behaviors to relieve altered symptom status is supported by this study. Patients in the 
adherent symptom monitoring group were more likely to recognize changes in symptoms 
(dyspnea or lower extremity edema) in a timely manner, respond to those changes, and 
evaluate the effectiveness of the responses as compared to patients in the partially 
adherent and non-adherent groups in this study. Dickson and colleagues introduced and 
defined three types of patients based on their self-care capacities: patients who are 
novice, inconsistent, and expert in self-care.167 A self-care expert is characterized as one 
who routinely performs “body listening,” makes a link between altered symptom status 
and its causes, chooses rational decisions about the changes, depends on lessons learned 
from previous experiences of symptom management, and reassesses the effectiveness of 
the actions taken.168 
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According to this self-care typology, patients in the adherent group in this study 
can be categorized as self-care experts because they performed adequate self-care 
management when symptoms of worsening HF occurred. Patients who vigilantly monitor 
their symptoms may have sufficient knowledge of HF mechanisms and causes of HF 
symptoms, and a good understanding of what to do to prevent HF exacerbation; however, 
it is beyond the purpose of this study to show whether patients in the adherent group had 
a better understanding of HF as compared to patients in the partially adherent and non-
adherent groups in this study.  
Adequate self-care management was associated with poor functional status in this 
study. Patients experiencing limited daily activities due to HF symptoms were more 
likely to perform adequate self-care management to avert an exacerbation of HF. Poor 
functional status due to HF symptoms may drive patients with HF to engage in self-care 
maintenance (e.g., symptom monitoring) and management (e.g., decreasing sodium 
intake) in order to maintain physical stability and/or ameliorate worsening HF.169-170  
One interesting finding in this study is the association between prescribed 
diuretics and self-care management. Diuretic prescription was an independent predictor 
of adequate self-care management, although the 95% CI for diuretic prescription in the 
logistic regression was wide.  Diuretics are considered the first-line treatment for patients 
with HF to achieve symptom control by preventing fluid overload. Flexible diuretic 
titration by capable patients is recommended in HF guideline and consensus 
statements.36,171 Patients in the adherent group were prescribed diuretics more and were 
more likely to take extra diuretics if changes in symptoms occurred than patients in the 
partially adherent and non-adherent groups in this study. Patients who were prescribed 
diuretics might have learned about flexible diuretic regimens from their healthcare 
providers and adjusted their diuretic dosage based on their symptoms, although this is 
speculation as we did not collect information on flexible diuretic titration by patients.  
Limitations of this study include limited generalizability. The sample in this 
study, which was predominantly male and white, makes it difficult to draw inferences 
from this study sample to all HF patients. Symptom monitoring behaviors and self-care 
management were assessed based on self-reporting, which may be subject to recall or 
social desirability bias. We used monitoring weight and lower extremity edema as a 
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measure of symptom monitoring behaviors. As weight gain and lower extremity edema 
are commonly experienced by patients with HF and have objective measures, patients 
may be able to compare and detect daily changes compared to changes in dyspnea, which 
may be affected by the degree of activities.  
Conclusion 
Adherence to regular symptom monitoring was associated with adequate self-care 
management. This result supports the conclusion that engaging in symptom monitoring is 
the first step in recognition of altered body states that prompts patients to proceed to 
appropriate self-care management in order to mitigate worsening symptoms. This, in turn, 
may decrease preventable hospitalizations due to failure to seek care in a timely manner. 
It is important to understand that lower extremity edema or weight gain alone cannot 
provide a complete picture of clinical deterioration. Thus, healthcare providers stress the 
importance of monitoring a group of relevant signs and symptoms of HF exacerbation to 
patients.  
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Table 5.1. Sample characteristics (N=311) 
 Total  
(N = 311) 
Non-
adherent  
(N = 174) 
Partially 
adherent  
(N = 90) 
Adherent 
(N = 47) 
p-
value 
Age, years  60 (11.9) 59 (12.5) 61 (10.2) 63 (11.9) 0.06 
Gender     0.50 
Male 201 (64.6%) 117 (67.2%) 54 (60.0%) 30 (63.8%)  
Female 110 (35.4%) 57 (32.8%) 36 (40.0%) 17 (36.2%)  
Marital Status     0.05 
Single/divorced/
widow 
126 (40.5%) 63 (36.2%) 46 (51.1%) 17 (36.2%)  
Married/co-
habitating 
185 (59.5%) 111 (63.8%) 44 (48.9%) 30 (63.8%)  
Ethnicity     0.01 
White 206 (66.2%) 105 (60.3%) 61 (67.8%) 40 (85.1%)  
Minority 105 (33.8%) 69 (39.7%) 29 (32.2%) 7 (14.9%)  
NYHA class     0.78 
I/II 112 (36.0%) 62 (35.6%) 31 (34.4%) 19 (40.4%)  
III/IV 199 (64.0%) 112 (64.4%) 59 (65.6%) 28 (59.6%)  
Ischemic etiology 
of Heart Failure 
220 (70.7%) 113 (64.9%) 68 (75.6%) 39 (83.0%) 0.03 
Ejection fraction     0.16 
≤ 40% 200 (64.3%) 107 (61.5%) 57 (63.3%) 36 (76.6%)  
> 40% 111 (35.7%) 67 (38.5%) 33 (36.7%) 11 (23.4%)  
Duke Activity 
Status Index scores 11.4 (11.8) 12.2 (13.2) 10.1 (10.2) 10.6 (8.2) 
0.35 
Chalson 
Comorbidity Index 3.3 (1.9) 3.2 (1.8) 3.6 (2.0) 3.5 (2.1) 
0.15 
Self-care 
Management† 55.5 (20.5) 49.4 (19.4) 59.9 (19.3) 70.0 (17.6) 
<.001 
Medications      
ACEI or ARB 
(n=310) 
254 (81.9%) 148 (85.1%) 71 (79.8%) 35 (74.5%) 0.20 
Beta Blocker 
(n=309) 
267 (86.4%) 149 (85.6%) 75 (85.2%) 43 (91.5%) 0.54 
Diuretics  245 (78.8%) 124 (71.3%) 75 (83.3%) 46 (97.9%) <.001 
Note. Values are mean (SD) or n (%). † Significant group difference among all three groups  
NYHA=New York Heart Association; ACEI = angiotensin converting enzyme inhibitor; ARB = 
angiotensin receptor blocker 
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Table 5.2.  Self-care management behaviors by symptom monitoring adherence groups 
(N=311) 
 Total  
(N = 311) 
Non-
adherent  
(N = 174) 
Partially 
adherent  
(N = 90) 
Adherent 
(N = 47) 
p-
value 
Symptom Recognition    <.001 
Not recognized 41 (13.2%) 33 (19.0%) 8 (8.9%) 0 (0.0%)  
Not quickly 30 (9.6%) 22 (12.6%) 5 (5.6%) 3 (6.4%)  
Somewhat quickly 44 (14.1%) 23 (13.2%) 15 (16.7%) 6 (12.8%)  
Quickly 85 (27.3%) 52 (29.9%) 25 (27.8%) 8 (17.0%)  
Very quickly 111 (35.7%) 44 (25.3%) 37 (41.1%) 30 (63.8%)  
Restrict Sodium Intake    0.011 
Not likely 29 (9.3%) 21 (12.1%) 7 (7.8%) 1 (2.1%)  
Somewhat likely 64 (20.6%) 40 (23.0%) 18 (20.0%) 6 (12.8%)  
Likely 79 (25.4%) 51 (29.3%) 16 (17.8%) 12 (25.5%)  
Very likely 139 (44.7%) 62 (35.6%) 49 (54.4%) 28 (59.6%)  
Restrict Fluid Intake     <.001 
Not likely 95 (30.5%) 66 (37.9%) 24 (26.7%) 5 (10.6%)  
Somewhat likely 65 (20.9%) 40 (23.0%) 19 (21.1%) 6 (12.8%)  
Likely 74 (23.8%) 40 (23.0%) 17 (18.9%) 17 (36.2%)  
Very likely 77 (24.8%) 28 (16.1%) 30 (33.3%) 19 (40.4%)  
Take an Extra Diuretics    0.030 
Not likely 112 (36.0%) 67 (38.5%) 34 (37.8%) 11 (23.4%)  
Somewhat likely 44 (14.1%) 30 (17.2%) 10 (11.1%) 4 (8.5%)  
Likely 63 (20.3%) 36 (20.7%) 19 (21.1%) 8 (17.0%)  
Very likely 92 (29.6%) 41 (23.6%) 27 (30.0%) 24 (51.1%)  
Call HealthCare Providers for Guidance   0.265 
Not likely 93 (29.9%) 53 (30.5%) 28 (31.1%) 12 (25.5%)  
Somewhat likely 57 (18.3%) 27 (15.5%) 19 (21.1%) 11 (23.4%)  
Likely 67 (21.5%) 46 (26.4%) 13 (14.4%) 8 (17.0%)  
Very likely 94 (30.2%) 48 (27.6%) 30 (33.3%) 16 (34.0%)  
Evaluation of Treatment Strategies (helpful or not)   <.001 
Did not try anything 62 (19.9%) 43 (24.7%) 12 (13.3%) 7 (14.9%)  
Not sure 48 (15.4%) 33 (19.0%) 12 (13.3%) 3 (6.4%)  
Somewhat sure 74 (23.8%) 49 (28.2%) 19 (21.1%) 6 (12.8%)  
Sure 67 (21.5%) 27 (15.5%) 22 (24.4%) 18 (38.3%)  
Very sure 60 (19.3%) 22 (12.6%) 25 (27.8%) 13 (27.7%)  
Note. Values are n (%).
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Table 5.3. Logistic regression (N=311) 
 Odds Ratio 95% Confidence Interval p-value 
Age 1.01 0.99 - 1.04 0.350 
Gender (Female vs. Male) 0.83 0.42 - 1.64 0.586 
Marital Status  
(Married/co-habitating vs. 
Single/separated/widowed) 
1.39 0.74 - 2.62 0.302 
Ethnicity (White vs. Minority) 1.44 0.73 - 2.84 0.296 
Chalson Comorbidity Index 0.93 0.79 - 1.10 0.396 
NYHA Class 
(III/IV vs. I/II) 
2.23 1.09 - 4.57 0.028 
Etiology of Heart Failure 
(Non-ischemic vs. Ischemic) 
0.77 0.37 - 1.61 0.487 
Ejection Fraction (≤ 40% vs. > 40%) 1.72 0.86 - 3.45 0.128 
Duke Activity Status Index scores 1.02 0.99 - 1.05 0.130 
Diuretic Prescription  6.02 1.76 - 20.64 0.004 
Symptom Monitoring Adherence 
Groups 
  0.005 
Partially Adherent Group  2.40 1.19 - 4.81 0.014 
Adherent Group 3.47 1.55 - 7.74 0.003 
Note. NYHA=New York Heart Association 
Model p-value <0.001 
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Figure 5.1. Adherence to symptom monitoring behaviors (N=311) 
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CHAPTER SIX 
A Symptom Diary Intervention to Improve Outcomes in Patients with HF: A Pilot Study 
Introduction 
Patients with heart failure (HF) must monitor for and recognize escalating 
symptoms in order to take action to relieve symptoms in a timely manner and decrease 
preventable hospitalizations. However, routine symptom monitoring is not commonly 
performed by patients with HF.172-175 For example, monitoring daily weight as a measure 
of fluid overload is performed by less than 50% of patients and only 5%-26% of these 
patients notice weight gain prior to requiring admission.85-86, 173, 175-176 When patients fail 
to monitor symptoms routinely they do not recognize the need to take action early (e.g., 
taking extra diuretics or consulting their healthcare provider) that could prevent emergent 
hospitalization. 
A delay in seeking care can occur when patients ignore or fail to recognize 
changes in HF symptoms.177 Patients who experience a gradual increase in symptoms 
(e.g., edema and dyspnea) wait up to seven days or more before seeking treatment, which 
can ultimately result in hospitalization for acute decompensated HF.27, 74, 85-86, 178 Other 
reasons for slow patient response time when experiencing worsening HF symptoms 
include a belief that chronic, non-specific HF symptoms are unimportant or are due to 
other causes, such as stress, aging or comorbid conditions.85-86, 178-179 Thus, it is essential 
that tools be developed to promote regular monitoring of symptoms by patients with HF.  
One tool that can promote symptom monitoring and recognition is a daily 
symptom diary. In one randomized controlled study testing the effect of using a weight 
diary in patients with HF, rates of one-year mortality were significantly lower in weight 
diary users versus non-users.180 When patients record presence and severity of symptoms 
on a daily basis, it may be easier for them to compare current symptom status to the past 
without relying on memory alone. In this way, patients may more rapidly recognize signs 
and symptoms of worsening HF.  
The aim of this study was to test the effect of a daily symptom diary intervention 
that included education and counseling about HF symptoms, how to recognize them, and 
what to do with escalating symptoms. The outcomes tested at 3-month follow-up were 
HF event-free survival, health-related quality of life (HRQOL), and self-care 
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maintenance. In this randomized controlled trial, I hypothesized that patients who 
received the intervention would have longer HF event-free survival and better HRQOL 
and  be more adherent to self-care maintenance compared to patients who did not receive 
the intervention. Additionally, I used changes in depressive symptoms as covariate 
because depressive symptoms are associated with outcomes of interest in this study. In 
this paper, I describe the design and intervention and report preliminary results of the 
trial. 
Methods 
Design and Procedure 
This pilot study was conducted using a two-group, randomized, repeated 
measures experimental design. Patients were recruited during their inpatient stay in one 
academic medical center and two community hospitals in Kentucky. Patients were 
identified from the hospital daily HF reports, in which patients’ names and locations were 
listed and were screened for their eligibility by hospital staff and the investigator. The 
investigator obtained signed, informed consent from all patients who agreed to participate 
in the study. A baseline assessment (within six weeks of hospital discharge) and two 
additional follow-ups at one month and three months from the baseline were done at 
either the College of Nursing at the University of Kentucky or patients’ houses by the 
investigator. Data stable over three months (e.g., age, gender, and living arrangement) 
were collected only at baseline. Data expected to change over three months (i.e., 
HRQOL, self-care maintenance, depressive symptoms, and New York Heart Association 
[NYHA] functional class) were collected at baseline, one month, and three months. Data 
about HF events were collected at three months. Patients were followed until death, loss 
to follow-up, or study completion. Patients voluntarily participated in this study without 
monetary compensation. 
Sample 
Patients who were diagnosed with HF and hospitalized for a cardiac-related 
reason were screened for their eligibility to this study. The study cohort was composed of 
patients who were 21 years or older, diagnosed as having HF with either preserved or 
non-preserved systolic function, able to read and speak English, and lived within two-
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hours driving distance from Lexington, KY. Exclusion criteria were: (1) currently using 
any type of symptom monitoring instruments; (2) having severe or life-threatening 
comorbidities (e.g., cancers, liver failure, or end stage renal failure); (3) awaiting cardiac 
transplantation; (4) not having a telephone; or (5) having cognitive impairment that 
prevented provision of informed consent, or inability to respond questions and fill out 
questionnaires.   
Randomization 
A random sequence was generated by a random number generating program. In 
order to ensure a good balance of participants in each group, a permuted block of four 
was used. When each patient’s baseline was scheduled, the investigator assigned them to 
the intervention or usual care group according to the randomization list. Patients and the 
investigators were not blinded to the group assignment of patients. 
Intervention Group 
Patients in the intervention group received the initial education and counseling 
session with introduction of the symptom diary in the College of Nursing at the 
University of Kentucky or their home, depending on their preference. The intervention 
was provided after initial data collection was completed. Thereafter, patients received a 
total of 5 booster sessions (i.e., supporting patients and reviewing education) via 
biweekly phone calls for three months.  
The face-to-face education and counseling session consisted of a simplified 
explanation of HF and how it causes symptoms, causes of worsening symptoms in 
relation to fluid retention and diet, how to monitor symptoms, what to do about 
worsening symptoms, and a review of the medication regimen. Symptoms of HF 
exacerbation (e.g., increased swelling, shortness of breath, and weight gain) were listed in 
the symptom diary. Information about how to manage altered symptom status was also 
provided (e.g., when to call their healthcare providers or criteria for taking extra diuretics, 
if they were prescribed) based on the HF Society of America guidelines.36 
Patients in the intervention group received a symptom diary to track their daily 
symptoms and record their weight for monitoring purposes. The symptom diary was a 
ledger type and had four sections: (1) daily weight; (2) rating the severity of each of 
seven symptoms (i.e., swelling of feet, hands, or abdomen; shortness of breath with 
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activity; shortness of breath at rest; difficulty sleeping; difficulty breathing when lying 
flat; waking up breathless at night; and feeling nervous); (3) rating the degree of activity 
limitation due to symptom status during a day (How much did you have to cut down your 
activity because of symptoms?); and (4) personal comments for noting symptoms other 
than the ones listed and actions taken to relieve symptoms. Patients were instructed to 
weigh themselves daily in the morning after the first urination in similar clothing before 
eating or drinking. A 6-point rating scale was used to rate symptom severity (0=no 
symptom to 5= extremely severe) and change in activity level (0=not at all to 5=stopped 
almost all activities). The adequacy of format and contents of the diary was confirmed by 
an expert panel (three experts in nursing and HF and one gerontology expert). 
After baseline, five booster sessions were done by the investigator. Patients 
received biweekly calls to discuss their experience with keeping the symptom diary, 
review changes in symptoms of HF, and subsequent actions that patients might have 
taken. The investigator encouraged patients to keep the symptom diary daily. 
Usual Care Group  
Usual care in the institutions used in this study included giving patients a 
discharge education booklet describing HF, a low sodium diet recommendation, and 
instructions to take medications as prescribed. Tools for symptom monitoring, such as a 
symptom diary, were not provided by healthcare providers as part of routine care.  
Measures 
Heart failure event-free survival. In this study, HF event-free survival was 
defined as the composite end point of time to first event of HF-related death or 
hospitalization, or emergency department visit for HF. Experts in HF and the investigator 
considered HF-related events as any hospital admission or emergency department visit 
related to worsening HF as a primary diagnosis, including acute on chronic HF, volume 
overload requiring intravenous diuretic therapy, dyspnea not primarily caused by 
pulmonary diseases, internal cardiac defibrillator (ICD) or biventricular pacemaker 
placement due to severe HF, ICD firing, or sudden cardiac arrest.  The data on these 
events were obtained from patients or their family at three months and confirmed with 
medical records.  
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Health-related quality of life. Health-related quality of life was measured with the 
Minnesota Living with HF Questionnaire (MLHFQ).181 The MLHFQ, a disease-specific 
HRQOL instrument, assesses a patient's perception of the impact of HF and HF treatment 
on physical, psychological, and social aspects of life. The MLHFQ contains 21 items 
rated by the patient using a 6-point Likert scale (0-5 points). Items are totaled to give a 
HRQOL score. The range of possible scores was 0 to 105, with higher scores indicating a 
worse HRQOL. This instrument is the most widely used measure of HRQOL in HF 
research. Reliability and validity of the instrument have been demonstrated multiple 
times in a variety of HF samples.182-184 In this study, Cronbach’s alpha coefficient for 
HRQOL scores at baseline was .93.  
Self-care maintenance. Self-care maintenance was quantified with the self-care 
maintenance subscale of the Self-Care of HF Index. The self-care maintenance subscale 
consists of 10 items, two items about monitoring symptoms for congestion (i.e., weight 
and lower extremity edema), and eight items about adherence to the recommended 
therapeutic regimens (e.g., doing physical activity, following low sodium diet, taking 
medications as directed, and keeping an appointment with healthcare providers). Scores 
on the self-care maintenance subscale were standardized to 100, with higher scores 
reflecting better self-care maintenance.  The reliability and validity of the Self-Care of 
HF Index in patients with HF has been supported.185 The internal consistency of the self-
care maintenance subscale measured with Cronbach’s alpha coefficient at baseline was 
.59 in this study.  
Depressive symptoms. The nine-item Patient Health Questionnaire (PHQ-9) was 
used to assess depressive symptoms. Items on the PHQ-9 reflect diagnostic criteria for 
major depression as described in the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition.131  Patients were asked to rate each item on a 4-point Likert scale 
(0–3) to indicate how often they have experienced the item from not at all (0) to nearly 
every day (3) over the last two weeks. Scores could range from 0 to 27, with higher 
scores indicating more depressed. Scores of 5, 10, 15, and 20 represent thresholds, 
indicating mild, moderate, moderately severe, and severe levels of depression symptoms, 
respectively. The psychometric soundness of the PHQ-9 has been demonstrated with 
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patients with cardiac disease.132, 186 Good internal consistency with Cronbach’s alpha 
coefficient of 0.85 was observed in this study. 
New York Heart Association functional class. New York Heart Association 
functional class is a simple summary measure of a patient's functional limitation resulting 
from characteristic symptoms of HF (e.g., dyspnea and fatigue). Patients’ functional 
status is categorized into four functional classes: class I (i.e., no limitation of ordinary 
physical activity due to HF symptoms), class II (i.e., slight limitation of physical 
activity), class III (marked limitation of physical activity), and class IV (inability to carry 
on any physical activity without discomfort).187 The investigator determined patients’ 
NYHA functional class via in-depth structured interview.  
Socio-demographic and clinical characteristics. Data about age, gender, 
education levels, ethnicity, and living arrangements were collected using a standard 
investigator-developed sociodemographic questionnaire. Medical records were reviewed 
to obtain medication regimens. Comorbidities at enrollment were assessed with the 
Charlson Comorbidity Index.64 Scores can range from 0 to 34, with higher scores 
indicating higher burden from comorbid conditions. 
Statistical Analyses 
Data were analyzed with SAS (version 9.3). Analyses were undertaken on an 
intention-to-treat basis. Baseline sociodemographic and clinical variables were compared 
between intervention and usual care groups with summary descriptive statistics. 
Comparisons of continuous variables between groups were made with independent t-tests 
and discrete variables with chi-square tests as appropriate. 
Kaplan–Meier curves with the log rank test were used to compare group 
differences in time to first HF event. Cox proportional hazards regression was also 
conducted to examine the effect of the intervention on HF event-free survival 
independent of baseline self-care maintenance scores. According to the Kolmogorov-type 
supremum tests, there was no violation of the assumption of proportional hazards. All 
patients who had baseline data were included in these survival analyses.   
Linear mixed models were conducted to examine the relationship between groups 
and changes in HRQOL and self-care maintenance over three months, after adjusting for 
NYHA functional class (time-variant covariate) and depressive symptom scores (time-
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variant covariate). Fixed effects were groups (i.e., intervention vs. usual care), time (i.e., 
at baseline, one month, and three months), the group-by-time interaction. Unstructured 
covariate structure was used as a pattern of within-subject autocorrelation among times 
due to unequal spaced follow-up times. I also used the same statistical method to examine 
the changes in depressive symptoms by group without adjusting for covariates. Only 
patients who had at least two observations were included in linear mixed model analyses.  
I calculated the post-hoc statistical power of the present investigation using 
nQuery Advisor 6.0 (version 4.0) to estimate a sufficient sample size for a future large-
scale study. The power analyses were done using a two-tailed test at the .05 significance 
level.  
Results 
Sample Characteristics 
Figure 1 reflects the flow of patients through the study and includes the number of 
patients screened, enrolled, and included in the analyses at each time point. A total of 44 
patients completed baseline assessment (23 patients in the intervention and 21 patients in 
the usual care groups). Of these 44 patients, two (4.5%) died and eight (18.2%) dropped 
out of the study during the three-month follow-up period. Except for ethnicity, there were 
no significant differences in baseline sociodemographic and clinical characteristics, and 
scores of HRQOL, self-care maintenance, and depressive symptoms between patients 
who dropped out of the study and patients who did not. There was a higher proportion of 
African Americans than Caucasians in patients who dropped out of the study compared to 
patients who did not (70.0% vs. 29.4%, p-value < .05).  
Baseline characteristics of patients in the intervention group are compared to 
those of patients in the usual care group in Table 1. The mean age of the total sample was 
60 years and ranged from 28 to 86 years. Patients were predominantly Caucasian and the 
majority lived with someone. The mean depressive symptom score was 9.5, indicating 
moderate depressive symptoms. Patients in the intervention group did not significantly 
differ in sociodemographic or clinical characteristics, scores of HRQOL or depressive 
symptom scores from patients in the usual care group.  
Table 2 presents the baseline characteristics of a subset of patients who had at 
least two follow-ups (N=36). There were no significant differences between patients in 
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this subset (n=36) and in patients with only one follow-up (n=8; four from intervention 
and four from usual care groups) with regard to all baseline sample characteristics.  
Primary Findings 
Heart Failure Event-free Survival. There were 14 HF events that occurred in eight 
patients (two patients in the intervention group vs. six patients in the usual care group) 
during the study: two deaths, nine hospitalizations, and three emergency department 
visits. The eight patients who had HF events were in NYHA functional class III or IV. A 
total of 11 HF events occurred in the usual care group (i.e., two deaths, six 
hospitalizations, and three emergency department visits), while three HF events occurred 
in the intervention group (i.e., three hospitalizations).  
The HF event-free survival curves by group are shown in Figure 2. Although not 
statistically significant, a trend is evident for patients in the intervention group to 
experience longer HF event-free survival compared to patients in the usual care group (p-
value =.07). Heart failure event-free survival was 91.3% (21/23) in the intervention group 
vs. 71.4% (15/21) in the usual care group. Cox regression analysis was performed to 
examine the association between HF event-free survival and intervention after adjusting 
for baseline self-care maintenance; however, the model was not significant. 
Health-related Quality of Life. The mean scores of HRQOL decreased over time 
(p-value < .01) in both the intervention and usual care groups (Figure 3). There were no 
differences in changes in HRQOL scores between groups over three months. When 
depressive symptoms and NYHA functional class were entered in the model as time-
variant covariates, the relationship between time and changes in HRQOL was no longer 
significant (p-value= .09); however, an increase in depressive symptoms was 
significantly associated with increases in HRQOL scores over three months (p-value < 
.001).  
Self-care Maintenance. There was an interaction between group and follow-up 
time in changes in self-care maintenance scores over three months (Figure 4). Self-care 
maintenance scores in the intervention group increased over time, while self-care 
maintenance scores in the usual care group decreased over time (p-value= .05). The 
interaction effect of group by follow-up time on changes in self-care maintenance scores 
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no longer remained significant (p-value= .06), after adjusting for depressive symptoms 
and NYHA functional class.  
Secondary Finding 
Depressive symptoms. There was an interaction effect of group by follow-up time 
(p-value= .02) on changes in depressive symptom scores (Figure 5). Depressive symptom 
scores in patients in the intervention group increased with time, while depressive 
symptom scores in patients in the usual care group decreased over time. 
Post-hoc Power Analysis  
Post-hoc power analyses were done to estimate power to detect group differences 
and estimate a sufficient sample size for future study based on the preliminary findings. 
The rate of HF events in the intervention group was 91.3% compared to 71.4% in the 
usual care group. The present study had a power of 35% to detect the group differences in 
HF event-free survival with a constant hazard ratio of 3.70 using a .050 level two-sided 
log-rank test for equality of survival curves. A total of 128 patients (64 per group) is 
required to detect the group differences in HF event-free survival with hazard ratio of 
3.70 with a power of .80.   
The estimated effect sizes (i.e., proportion of the variance attributed to the fixed 
effect of interest) of HRQOL and self-care maintenance with partial eta were .14 and .01, 
respectively. The post-hoc power analyses indicated that we had 15% and 5% of power to 
detect the group differences in HRQOL and self-care maintenance, respectively. If we 
increase sample size of 64 per group, which was estimated from the post-hoc power 
analysis for HF event-free survival, the power to detect the group differences in HRQOL 
will increase to 75%, while the power in self-care maintenance will be the same as 5%.  
Feasibility and Acceptability 
This pilot study provided evidence of the feasibility of using a daily symptom 
diary in HF patients. No patients dropped out because they found the diary too hard to 
use. The time to complete the diary daily was about up to 15 minutes according to 
patients. Patients said that examples in the diary helped them to understand how to use 
the diary. According to some patients, forgetting, traveling, feeling depressed, or being 
hospitalized were reasons that symptoms and weights were not monitored using the diary. 
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A 30-day diary adherence score was computed based on a formula created by 
White and colleagues:188 dividing the number of days patients rated symptoms or 
weighed themselves by 30 days. The mean adherence scores in each item in the diary 
ranged from 87.6% to 90.3%. These adherence scores were higher than adherence scores 
of daily weight reported in the study of White and colleagues (79.4%).188 These high 
adherence scores suggest that patients adhered well to the diary.  
Patients in the intervention group made positive comments about using the daily 
symptom diary. One patient said that information about daily symptoms and weight 
enabled him to distinguish weight gain from retaining fluid rather than weight gain due to 
adiposity and understand the relationship between his dietary habits and fluid retention.  
Another patient mentioned that monitoring daily weight and symptoms became her 
routine because of the diary. 
Discussion 
This randomized, controlled trial was a pilot study to test the feasibility of using a 
daily symptom diary with education and counseling sessions in patients with HF, aimed 
at the improvement of outcomes in patients with HF, prior to designing a future large-
scale study. I found no statistically significant differences between the intervention and 
usual care groups in HF event-free survival, and changes in HRQOL and self-care 
maintenance. However, I did find a trend for improvement in the intervention group in 
HF event-free survival and self-care maintenance over time. Despite the small sample 
size, which limited power to detect a statistical significance, findings from this study 
suggest a potential positive impact of daily symptom diary use along with education and 
counseling sessions on outcomes in patients with HF.  
The post-hoc power analysis was done to plan for a future study. As expected, the 
power to detect the group differences in HF event-free survival between the two groups 
was 35%. Although this pilot study was underpowered, there were promising trends 
toward improved outcomes in HF event-free survival and self-care maintenance. I 
calculated the effect size and can now accurately determine the sample size needed for an 
adequately powered full scale randomized controlled trial. 
Keeping a symptom diary helps patients pay attention to their bodily changes and 
detect early symptoms of HF exacerbation,7 which may decrease preventable 
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hospitalizations.180, 189 The advantages of keeping a diary on prognosis were observed in 
previous studies.180, 189 Patients with HF who used a weight diary had a fewer number of 
readmissions and more days alive without repeated hospitalizations than patients who did 
not use a weight diary.180  
I did not find a significant association between the intervention and HF event-free 
survival. However, the survival curves began to separate by approximately 25 days after 
baseline. There were five patients who had their first HF event within 30 days; of these 
five patients, four were in the usual care group while one was in the intervention group. 
High NYHA class is associated with high rates of mortality and hospitalization in 
patients with HF,190-192 which was consistently found in this study. In this study, only 
patients in NYHA functional class III and IV had HF events. Patients in the intervention 
group had fewer HF events than patients in the usual care group, despite the fact that 
there were no group differences in the proportion of patients in NYHA functional class. 
This finding suggests that the intervention in this study could negate the adverse impact 
of high NYHA functional class, a well-established risk factor for poor prognosis, 
although further investigation is required. 
To be an expert in HF self-care, two types of skills are required: tactical skills, 
which involves the “how to” of adhering to the recommended regimens, and situational 
skills, which involves action plans of “what to do when.”193 The intervention in this study 
may benefit patients to build these skills by providing a symptom diary (i.e., tactical 
skills for symptom monitoring) with clear instructions in the diary about what to do when 
changes in symptoms are noticed (i.e., situational skills). In addition to this, deliberate 
efforts of monitoring and recording symptoms may help patients make associations 
between symptoms and their behaviors (e.g., diet)189 and recognize precipitating factors 
of HF exacerbation. Once patients learn these associations, they may be more adherent to 
recommended regimens, such as following a low sodium diet and taking medication as 
directed, to prevent escalating symptoms of HF. These possible benefits of keeping a 
diary were observed in this study. At three months after the intervention, the mean score 
of self-care maintenance (i.e., symptom monitoring and adherence to therapeutic 
regimens) in patients in the intervention group was above 70 (75.6 ± 9.6), indicating 
adequate self-care maintenance,185 while the mean score in patients in the usual care 
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group was below 70 (68.0 ± 11.1), indicating inadequacy of self-care maintenance. 
However, this difference was not statistically significant and further investigation with an 
adequate sample size is needed before conclusions can be reached. 
The positive effects of keeping a diary on self-care behaviors were found in 
previous studies, in which adequate sample sizes were used. Caldwell and colleagues 
provided HF patients with a weight diary and one-time education focusing on symptom 
recognition and fluid weight management at baseline and a phone call at one month for 
reinforcement.194 In this study, patients in the intervention group were more likely to be 
knowledgeable about HF and adherent to daily weight monitoring than patients in the 
control group at three months after the intervention. Wright and colleagues also 
demonstrated the benefits of keeping a diary.180  Patients who used weight diaries, 
defined as weight monitoring at least once a week, were more likely to call their 
healthcare provider, compared to those who did not use weight diaries.180 Thus, a daily 
symptom diary may be beneficial as a guide and reminder for patients to perform self-
care activities.  
Natural improvement in HRQOL after hospital discharge was observed in many 
previous studies, and highlights the importance of including control groups in 
intervention trials over simply using pre-post test designs.195-196 This trend for improved 
HRQOL was found in both groups at one-month follow-up in this study.  
To examine the effect of outliers on HRQOL scores, an additional analysis was 
done without adjusting for depressive symptoms and NYHA functional class after 
patients (n=7), whose HRQOL scores were in the high and low tenth percentiles, were 
removed. Without outliers, there was a trend for patients in the intervention group to 
report better HRQOL than patients in the usual care group over time.  
There are several limitations in this pilot study. The main weakness of this study 
was its relatively small sample size which limited the power to detect a statistically 
significant effect on outcomes. However, I believe that the sample size achieved has 
allowed us to demonstrate that this approach to using a daily symptom diary is a feasible 
method to employ with patients with HF and further investigation of the intervention in 
an adequately powered study is warranted. Because of limited resources, the investigator 
delivered the intervention and collected outcome variables. In order to minimize possible 
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bias from doing the intervention and data collection by one person who was not blinded 
to group assignment, HF events were predefined by the investigator and an HF expert. 
Any ambiguity related to HF event was discussed with the HF expert.  
Future Study 
To improve this pilot study, three elements will be added. B-type natriuretic 
peptide (BNP), which is a cardiac neurohormone secreted from the ventricles in response 
to volume expansion and pressure overload, will be included as an outcome measure.  By 
measuring BNP levels, I may evaluate the effectiveness of keeping a symptom diary in an 
objective way.  
Motivational interviewing will be used to improve patients’ adherence to keeping 
a symptom diary. Motivational interviewing is a one-to-one client-centered counseling 
technique known to increase patients’ self-efficacy and support patients’ autonomy.197 
There is evidence showing that adopting motivational interviewing as a way of delivering 
the intervention is effective in promoting behavioral changes.197-198 
I will include patients’ healthcare providers in a future intervention because they 
are influential in promoting patients’ adherence to a symptom diary. I encouraged study 
participants to show their symptom diaries to healthcare providers. One patient made the 
copy of his diary and showed it to his doctor. However, his doctor did not look at his 
diary with him and told him that he would read it later. The patient was so disappointed 
and upset with his doctor’s attitude.  Another patient who showed her diary to her doctor 
received positive feedback on keeping the diary. She was motivated to continue keeping 
her symptom diary. Although these are anecdotal evidence, there are studies illustrating 
similar observations. In a previous study, patients did not perform symptom or blood 
pressure monitoring because the data were not reviewed by their healthcare providers and 
thus patients did not know how to use the data.199 By including healthcare providers in a 
future study, we may increase adherence to the diary.   
Conclusions 
Optimal management of HF can be achieved with active self-care engagement by 
patients, as the majority of HF care, such as daily symptom monitoring and medication 
adherence, is performed by patients at home. The intervention used in this study was 
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designed to promote patients’ symptom monitoring behaviors by providing a daily 
symptom diary with education and counseling sessions. Patients in the intervention group 
took an active role in their care and demonstrated a trend toward the improvement in self-
care maintenance and fewer HF events. Based on the results of this study, I plan a full-
scale randomized controlled trial with an adequate sample size. 
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Table 6.1. Characteristics of sample by groups (N=44) 
 Total 
(N = 44) 
Usual care group
(N = 21) 
Intervention 
group 
(N = 23) 
p-value 
 N (%) or mean ± SD  
Age, years 60 ± 12 61 ± 13 60 ± 12 0.94 
Gender    0.55 
Male 23 (52.3%) 10 (47.6%) 13 (56.5%)  
Female 21 (47.7%) 11 (52.4%) 10 (43.5%)  
Living alone 15 (34.1%) 6 (28.6%) 9 (39.1%) 0.46 
Ethnicity    0.49 
African American 17 (38.6%) 7 (33.3%) 10 (43.5%)  
Caucasian 27 (61.4%) 14 (66.7%) 13 (56.5%)  
Education     0.50 
< High school 3 (6.8%) 2 (9.5%) 1 (4.3%)  
≥ High school 41 (93.2%) 19 (90.5%) 22 (95.7%)  
Comorbidity 4.1 ± 2.4 4.6 ± 2.6 3.8 ± 2.2 0.31 
NYHA class    0.37 
I/II 22 (50.0%) 9 (42.9%) 13 (56.5%)  
III/IV 22 (50.0%) 12 (57.1%) 10 (43.5%)  
Left ventricular ejection 
fraction, % 38.7 ± 15.9 37.7 ± 16.5 39.7 ± 15.6 0.69 
Ischemic etiology of HF 16 (36.4%) 6 (28.6%) 10 (43.5%) 0.31 
Medication therapy     
ACEI or ARB 25 (56.8%) 10 (47.6%) 15 (65.2%) 0.24 
Beta Blocker 35 (87.5%) 17 (89.5%) 18 (85.7%) 0.72 
Diuretics 32 (80.0%) 15 (78.9%) 17 (81.0%) 0.87 
Self-care maintenance 66.9 ± 15.9 71.4 ± 14.0 62.7 ± 15.2 0.06 
Health-related quality of 
life 66.6  ± 24.6 68.4 ± 22.8 64.9 ± 26.5 0.65 
Depressive symptoms 9.5 ± 6.5 10.1 ± 6.4 9.0 ± 6.6 0.57 
Note. NYHA=New York Heart Association; HF= Heart Failure; ACEI = angiotensin converting 
enzyme inhibitor; and ARB = angiotensin receptor blocker 
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Table 6.2. Subset sample characteristics by groups (N=36) 
 Total 
(N = 36) 
Usual care group 
(N = 17) 
Intervention 
group 
(N = 19) 
p-
value 
 N (%) or mean ± SD  
Age, years 62 ± 12 62 ± 12 62 ± 12 0.98 
Gender    0.52 
Male 19 (52.8%) 8 (47.1%) 11 (57.9%)  
Female 17 (47.2%) 9 (52.9%) 8 (42.1%)  
Living alone 12 (33.3%) 5 (29.4%) 7 (36.8%) 0.64 
Ethnicity    0.64 
African American 12 (33.3%) 5 (29.4%) 7 (36.8%)  
Caucasian 24 (66.7%) 12 (70.6%) 12 (63.2%)  
Education     0.22 
< High school 2 (5.6%) 2 (11.8%) 0  
≥ High school 34 (94.4%) 15 (88.2%) 19 (100%)  
Comorbidity 4.0 ± 2.5 4.3 ± 2.7 3.7 ± 2.4 0.48 
NYHA class    0.30 
I/II 16 (44.4%) 6 (35.3%) 10 (52.6%)  
III/IV 20 (55.6%) 11 (64.7%) 9 (47.4%)  
Left ventricular 
ejection fraction, % 38.1 ± 16.3 37.6 ± 16.8 38.5 ± 16.3 0.87 
Ischemic etiology of 
HF 12 (33.3%) 4 (23.5%) 8 (42.1%) 0.24 
Medication therapy     
ACEI or ARB 21 (58.3%) 8 (47.1%) 13 (68.4%) 0.19 
Beta Blocker 29 (85.3%) 14 (87.5%) 15 (83.3%) 0.73 
Diuretics 27 (79.4%) 12 (75.0%) 15 (83.3%) 0.55 
Self-care maintenance 67.7 ± 15.1 72.1 ± 13.9 63.7 ± 15.4 0.09 
Health-related quality 
of life 67.4 ± 23.7 67.1 ± 24.7 67.8 ± 23.5 0.93 
Depressive symptoms 9.8 ± 6.2 10.2 ± 6.3 9.4 ± 6.3 0.70 
Note. NYHA=New York Heart Association; HF=heart failure; ACEI = angiotensin converting 
enzyme inhibitor; and ARB = angiotensin receptor blocker 
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Figure 6.1. Study flow diagram 
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Figure 6.2. Kaplan–Meier curves (N=44) 
 
Follow-up days 
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Figure 6.3. Changes in health-related quality of life by group (N=36) 
 
 
Note. Higher scores indicate worse health-relate quality of life. 
According to the linear mixed model, follow-up time (p-value= .09), group (p-value= .29), and 
interaction group by follow-up time (p-value= .86) were not significantly associated with changes 
in health-related quality of life scores over three months, after adjusting for changes in depressive 
symptom scores (p-value < .001) and New York Heart Association functional class (p-value= 
.62).    
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Figure 6.4. Changes in self-care maintenance by group (N=36) 
 
Note. Higher scores indicate better self-care maintenance. 
 
According to the linear mixed model, there was not an interaction effect of group by follow-up 
time (p-value=.06) on changes in self-care maintenance scores, after adjusting for changes in 
depressive symptom scores and New York Heart Association functional class.   
 
 
98 
 
Figure 6.5. Changes in depressive symptoms by group (N=36) 
 
 
Note. Higher scores indicate more depressed. 
According to the linear mixed model, there was an interaction effect of group by follow-up time 
(p-value=.02) on changes in depressive symptom scores.   
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CHAPTER SEVEN 
Conclusions and Discussion 
The purpose of chapter seven is to summarize and synthesize the findings of this 
dissertation and provide implications for clinicians and researchers. Symptoms are a 
distinctive feature of heart failure (HF) and substantially influence outcomes.10, 55, 200-201 
Despite the importance of symptoms in this population, there are few investigations 
regarding how, and with which instruments, to accurately assess patients’ symptom 
experiences. This symptom measurement issue was addressed in three of five papers in 
this dissertation: (1) “Symptom Clusters in Men and Women with Heart Failure and 
Their Impact on Cardiac Event-Free Survival”; (2) “Heart Failure Symptom Measures: 
Systematic Review; and (3) “Association of Physical versus Affective Depressive 
Symptoms with Cardiac Event-Free Survival in Patients with Heart Failure.” 
Worsening symptoms of HF are the main reason for patients with HF to be 
hospitalized. It is believed that regular symptom monitoring with accurate measures 
enables patients to quickly recognize cues of worsening HF and take action, which may 
reduce preventable hospitalizations. However, it is not well studied whether patients who 
monitor worsening symptoms of HF are able to adequately respond to altered symptom 
status. If regular symptom monitoring leads to successful symptom management, 
developing a tool to assist patients’ regular symptom monitoring is essential because 
there are no such tools and patients have considerable difficulty monitoring and 
recognizing symptoms on their own.176, 202 The relationship between adherence to regular 
symptom monitoring and effective self-care management was investigated in chapters 
four and five: “Association between Regular Symptom Monitoring and Self-Care 
Management in Patients with HF” and “A Symptom Diary Intervention to Improve 
Outcomes in Patients with HF: a Pilot Study.” 
The motive for the first paper17 was the inadequacy of the current practice and/or 
research in which symptoms are considered as individual, isolated entities, when patients 
with HF usually experience a wide range of symptoms simultaneously. Investigations of 
individual symptoms help increase our understanding of the particular symptoms; 
however, this approach may not illustrate the complete picture of patients’ symptom 
experiences and can decrease our ability to appreciate the possible synergistic effects of 
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co-occurring symptoms on outcomes. Thus, I examined how symptoms clustered together 
and how symptom clusters affected outcomes. 
I found that two distinct symptom clusters emerged from seven individual 
physical and psychological HF symptom items: (1) a physical symptom cluster and (2) an 
emotional/cognitive symptom cluster. The emotional/cognitive symptom cluster was 
associated with increased risk of a cardiac event while the physical symptom cluster was 
not.  Characteristics among groups formed according to high and low scores of the two 
symptom clusters were also compared. Patients in the high distress group from the 
emotional/cognitive symptom cluster were younger and more symptomatic than patients 
in other groups.  
Findings from this chapter suggested that healthcare providers should assess 
symptom clusters and pay special attention to patients who are at risk for poor outcomes 
(e.g., younger patients) in relation to symptom clusters. Healthcare providers should 
teach patients to monitor multiple symptoms together to effectively recognize changes in 
HF status. As early symptoms of HF exacerbation lack specificity,203 it may be hard for 
patients with HF, especially those with comorbid conditions, to link these non-specific 
symptoms to their cardiac condition. Of 12 physical symptoms of HF, fatigue, weight 
gain, and dyspnea on exertion were grouped in a cluster in the study of Jurgens and 
colleagues.204 Patients may not consider feeling tired as a manifestation of worsening HF, 
unless they notice other symptoms of congestion, such as weight gain and dyspnea on 
exertion.203 The knowledge of symptom clusters may assist patients to discern whether 
symptoms are attributed to HF or other conditions.  
One challenge to adequately assessing symptoms or identifying symptom clusters 
is the lack of symptom instruments that include a variety of symptoms. There is no “gold 
standard” symptom instrument in the HF population.  To assess symptoms some 
investigators15-17 used items related to symptoms from HF-specific quality of life 
measures. Others9, 33, 205 used symptom measures developed for other populations, yet did 
not fully examine their psychometric properties in the HF population.  
In chapter three, symptom measures that were developed for and used in patients 
with HF were identified and examined for their quality in five evaluation categories (i.e., 
contents, measuring scales, psychometric properties, completion process, and 
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information). Five symptom instruments were included: the M.D Anderson Symptom 
Index-HF, the Memorial Symptom Assessment Scale-HF, the HF Signs and Symptoms 
Checklist, the HF Symptom Checklist, and the HF Symptom Survey. In this chapter, it 
was concluded that all five symptom instruments did not satisfactorily meet the 
evaluation categories. This may have occurred because the five symptom instruments 
reviewed were recently developed or revised for patients with HF and have not yet been 
rigorously examined for their psychometric properties. No instrument had the capability 
of assessing for symptom clusters. In this chapter, ongoing validation of the five 
symptom instruments was recommended to demonstrate their reliability and validity. 
Contents of symptom measures should be evaluated by experts and patients. Consensus 
among experts is necessary in order to capture symptoms in a measurable way to promote 
effective symptom management. In some measures, similar symptom items were assessed 
separately, while in others these symptom items were combined.  It is necessary to study 
how well patients can differentiate similar symptom items (e.g., feeling nervous from 
feeling anxious), which may serve as a guide to develop or modify symptom items.  
Chapter four also addressed a measurement issue regarding the possible over 
estimation of the relationship between depressive symptoms and outcomes due to 
overlapping physical depressive symptoms and typical HF symptoms. One issue in 
assessing depressive symptoms is that established, popular depressive symptom measures 
include physical depressive symptoms, which are frequently reported HF symptoms. This 
calls into question the association between poor outcomes and depressive symptom 
scores measured with instruments that include physical depressive symptoms, because 
depressive symptom scores may be a reflection of HF severity rather than a depressed 
mood.  
In chapter four, I evaluated whether the presence of physical depressive 
symptoms on the Patient Health Questionnaire-9 (PHQ-9), an established depressive 
symptom measure, exaggerated the association between depressive symptoms and 
cardiac event-free survival. In chapter four, it was concluded that physical depressive 
symptoms were not an independent predictor of cardiac event-free survival, but affective 
depressive symptoms were. This finding suggested that therelationship between 
depressive symptoms and risk for a cardiac event is not altered by the presence of 
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physical depressive symptoms. Outcomes can be accurately predicted based on 
depressive symptom scores using an instrument containing physical depressive 
symptoms.  
As HF is a chronic condition, patients with HF are in the best position to monitor 
and recognize their own worsening symptoms, and regular symptom monitoring may 
result in proper, timely response to altered symptom status.  In chapters five and six, 
investigations concerning patients’ symptom assessment as a part of self-care 
maintenance were conducted.  
Although it is suggested that regular symptom monitoring facilitates patients’ 
actions to mitigate worsening symptoms, it is questionable whether patients who are 
adherent to daily symptom monitoring are able to adequately perform self-care 
management behaviors to alleviate symptoms. In a study by Nieuwenhuis and 
colleagues,206 adherence to regular weight monitoring was not an independent predictor 
of seeking timely medical care. This finding suggested that patients do not follow 
recommendations for appropriate responses even if they recognize symptom changes and 
thus, miss the opportunity for timely intervention. Thus, in chapter five, the association 
between symptom monitoring behaviors (i.e., weight and lower extremity edema 
monitoring) and self-care management (i.e., response to changes in symptom status) was 
examined among HF patients who experienced dyspnea and lower extremity edema over 
the past month. I found that adequacy of self-care management was predicted by 
adherence to symptom monitoring behaviors. This finding suggested that regular 
symptom monitoring promotes the performance of subsequent self-care management, 
which may prevent hospitalizations in patients with HF.  
The findings from chapter five gave me the confidence to develop an intervention 
to improve symptom monitoring behaviors in patients with HF in order to improve 
outcomes. In chapter six, a randomized controlled pilot study was conducted to test the 
effect of a symptom diary intervention (providing a symptom diary, self-care education, 
and counseling) on HF event-free survival, health-related quality of life (HRQOL), and 
self-care maintenance (i.e., symptom monitoring behaviors and adherence to therapeutic 
regimens) in patients with HF at 3-month follow-up. A total of 44 HF patients recently 
discharged from the hospital were randomly assigned into usual care or intervention 
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groups. There were trends toward the improvement in HF event-free survival and self-
care maintenance over time in the intervention group, although these relationships did not 
reach statistical significance. There was no impact on HRQOL of the intervention. These 
findings suggest that a use of a simple daily symptom diary may promote patients’ 
symptom monitoring behaviors, which enhances patients’ self-care ability and facilitates 
timely intervention if symptom changes occur. Most importantly, these findings provide 
effect size data for use to determine the sample size needed for an adequately powered 
randomized controlled trial of the intervention.  
Implications 
This dissertation contributes to the science of HF management that focuses on 
symptoms by: (1) questioning the current practice of HF symptom assessment by 
healthcare providers and/ or researchers; (2) suggesting possible approaches to how 
symptom assessment can be effectively conducted; (3) providing evidence that daily 
symptom monitoring behaviors promote appropriate actions to respond altered symptom 
status; and (4) providing a potential strategy to enhance routine symptom monitoring 
behaviors in patients with HF.  There are two major implications for HF symptom 
assessment: how we assess symptom experiences of HF patients in a meaningful way and 
how we facilitate patients’ routine symptom monitoring behaviors to improve outcomes. 
Implications for Researchers  
One of the purposes of symptom assessment in HF is to understand patients’ 
symptom experiences, in order to develop and/or administer effective interventions to 
effectively manage symptoms. The current symptom instruments used in the HF 
population may not fulfill this purpose. Symptom clusters are not addressed in symptom 
instruments, despite the significant association between symptom clusters and outcomes. 
It is necessary to develop proper ways of addressing symptom clusters in HF symptom 
measures.  
One way to assess symptom clusters may be to conduct (1) a qualitative study 
with patients who recently had HF exacerbation to explore their symptom experiences 
focusing on the presence of symptom clusters; and (2) a quantitative study with the same 
population to conduct cluster analyses, based on results from symptom assessments using 
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a symptom instrument including a wide range of symptoms. By comparing results from 
the qualitative and quantitative studies, the presence and types of symptom clusters can 
be identified. The validity of the identified symptom clusters can be demonstrated by 
examining the association between the symptom clusters and outcomes, such as cardiac 
events and HRQOL, and by determining whether these symptom clusters are common in 
other HF patient populations, including subgroups such as patients with diabetes. 
Some symptom instruments include multiple items, which appear to measure a 
similar symptom. However, it is unknown how well patients can differentiate these 
similar symptom items. In addition, symptoms are operationalized in a variety of ways, 
which opens the question about how this information can be compared among different 
symptom measures or meaningfully used to promote symptom management. Thus, it is 
essential that researchers in the field discuss these issues in order to modify existing 
symptom measures or develop new measures . For example, in international meetings, 
such as annual American Heart Association and HF Society of America conferences, HF 
experts can discuss this issue related to effective symptom assessment.  The consensus 
from HF experts needs to be validated with clinicians and patients.   
This dissertation demonstrated, in an observational study, that regular symptom 
monitoring is associated with the appropriate self-care management, which ultimately 
contributes to outcome improvement in HF. However, the results from chapter six, an 
intervention pilot, showed trends toward reduced rates of HF events and enhanced self-
care maintenance after using a daily symptom diary. Due to the small sample size in this 
pilot study, there was limited power to detect the effect of the intervention. Further 
studies with a larger sample size are needed to support the effectiveness of a daily 
symptom diary use in patients with HF. Such studies are worthy of the attention of 
researchers given the preliminary findings in this study and the results of prior studies. 
Implications for Clinicians  
The concept of symptom clusters has an important implication for clinicians 
because symptoms occur together and symptom clusters are associated with outcomes.  
In clinical settings, clinicians should address the presence of symptom clusters when 
teaching patients. With knowledge of symptom clusters, patients can be aware of the fact 
that worsening symptoms of HF occur simultaneously, and monitor symptoms relevant to 
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HF together. It may help patients to take action in a timely manner before emergent 
interventions are required. 
It is too early to recommend which symptom clusters should be addressed because 
science of symptom cluster analysis in the HF population is at an early stage. There are 
few studies focusing on identifying symptom clusters and evaluating their impact on 
outcomes. Also, symptom measures used in previous research had a limited number of 
symptom items. Although more studies are needed regarding symptom clusters, it is 
important for clinicians to address the concept of symptom clusters when teaching 
patients.  
The median risk-adjusted 30-day readmission and mortality after hospitalization 
for HF were 24% and 11%, respectively.207 As patients with HF are vulnerable to poor 
outcomes during the period following discharge, increased surveillance of patients’ 
condition is essential.  
The findings from the pilot study in chapter six also offer a strategy to help 
patients monitor symptoms on a daily basis. 
One approach may be providing a daily symptom diary to patients as routine HF 
care. Patients would be able to quickly recognize and react to HF deterioration with the 
information in the symptom diary, which may result in better outcomes.  The information 
from the diary is also beneficial for clinicians to understand daily symptom experience 
and patients’ self-care practice at home and provide individualized advice regarding 
symptom management and self-care. Another merit of a daily symptom diary is that it is 
simple and easy to use regardless of patients’ education and not resource-intensive to 
administer. Thus, a daily symptom diary is a viable option for clinicians to routinely use 
in their HF care.  
Conclusions 
Accurate symptom assessment and management in HF are important because 
symptom status has serious consequences. The results of this dissertation revealed that 
existing symptom instruments in HF were not satisfactory to capture accurate symptom 
experiences and address symptom clusters. Collaborative efforts among researchers, 
clinicians, and patients are required to advance HF symptom assessment.  
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Routine symptom monitoring is important for patients to properly manage altered 
symptom status and prevent a delay in seeking care. The pilot study in this dissertation 
offers a promising strategy, a daily symptom diary, to enhance patients’ regular symptom 
monitoring behaviors. In this pilot study, daily symptom diary users tended to have fewer 
HF events and better self-care maintenance compared to daily symptom diary non-users. 
This simple diary is easy to implement by clinicians and acceptable by patients. 
However, more studies are needed to demonstrate a positive impact of a daily symptom 
diary use on outcomes in HF. 
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